MRI-guided interventions for fast diagnosis and focal treatment of (recurrent) prostate cancer by Overduin, C.G.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/178910
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.
FOR FAST DIAGNOSIS AND 
FOCAL TREATMENT OF
(RECURRENT) PROSTATE CANCER
MRI-GUIDED
INTERVENTIONS
KRISTIAN OVERDUIN
M
R
I-G
U
ID
ED
 IN
T
E
R
V
E
N
T
IO
N
S
K
R
ISTIA
N
 O
V
ER
D
U
IN
The work presented in this thesis was carried out within the Radboud Institute for Health Sciences. 
The research of this thesis was supported by and performed at the department of Radiology and 
Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
Publication of this thesis was financially supported by Radboudumc, Siemens Healthineers, 
NORAS MRI products, Soteria Medical, MML Medical and Guerbet Nederland.
ISBN
978-94-028-0834-6
Cover
Studio Gerton Hermers, Heumen
Lay-out
Studio Gerton Hermers, Heumen
Print
Ipskamp Printing, Enschede
© Kristian Overduin, 2017
Proefschrift
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken
volgens besluit van het college van decanen
in het openbaar te verdedigen op maandag 18 december 2017
om 16:30 uur precies
door
Christiaan Gerardus Overduin
geboren op 26 maart 1988
te Arnhem
FOR FAST DIAGNOSIS AND 
FOCAL TREATMENT OF
(RECURRENT) PROSTATE CANCER
MRI-GUIDED
INTERVENTIONS
Promotoren
Prof. dr. J.O. Barentsz
Prof. dr. J.J. Fütterer (Universiteit Twente)
Copromotor
Dr. ir. T.W.J. Scheenen
Manuscriptcommissie
Prof. dr. C. Rosman (voorzitter)
Prof. dr. P.F.A. Mulders
Prof. dr. ir. C.H. Slump (Universiteit Twente)
911
27
29
45
63
65
79
99
117
139
141
157
164
167
168
169
SECTION 1 INTRODUCTION
Chapter 1 General introduction, thesis aim and outline 
SECTION 2 MR-GUIDED PROSTATE BIOPSY
Chapter 2 MRI-guided biopsy for prostate cancer detection: 
 a systematic review of current clinical results
 Overduin CG, Fütterer JJ, Barentsz JO. Curr Urol Rep. 2013.
Chapter 3 Real-time targeting during 3-T in-bore MR-guided prostate biopsy 
 using a tablet device: a feasibility study
 Overduin CG, Heidkamp J, Rothgang E, Barentsz JO, de Lange F, Fütterer JJ. Submitted.
SECTION 3 MR-GUIDED PROSTATE CRYOABLATION
Chapter 4 T1-weighted MR image contrast around a cryoablation ice-ball: 
 a phantom study and initial comparison with in vivo findings
 Overduin CG, Bomers JG, Jenniskens SF, Hoes MF, Ten Haken B, de Lange F, Fütterer JJ, 
 Scheenen TW. Med Phys. 2014.
Chapter 5 3D MR thermometry of frozen tissue: feasibility and accuracy 
 during cryoablation at 3T
 Overduin CG, Fütterer JJ, Scheenen TW. J Magn Reson Imaging. 2016.
Chapter 6 Focal salvage MRI-guided cryoablation for localized prostate cancer 
 recurrence after radiotherapy: 12 month follow-up
 Bomers JG, Overduin CG, Jenniskens SF, Cornel E, van Lin E, Sedelaar JP, Fütterer JJ. Submitted.
Chapter 7 Percutaneous MR-guided focal cryoablation for recurrent prostate cancer 
 following radiation therapy: retrospective analysis of ice-ball margins 
 and outcomes
 Overduin CG, Jenniskens SF, Sedelaar JP, Bomers JG, Fütterer JJ. European Radiology. 2017.
SECTION 4 SUMMARY AND DISCUSSION
Chapter 8 Summary, discussion and future perspectives
Chapter 9 Samenvatting
APPENDICES – List of publications and presentations
 – PhD training portfolio
 – Curriculum vitae
 – Dankwoord
TABLE OF CONTENTS
LIST OF ABBREVIATIONS
3D  Three dimensional
AUC  Area under the curve
BPH  Benign prostatic hyperplasia
bSSFP  Balanced steady state free precession
CZ  Central zone
DCE  Dynamic contrast enhanced imaging
DRE  Digital rectal examination
DWI  Diffusion-weighted imaging
FA  Flip angle
GRE  Gradient recalled echo
MR  Magnetic resonance
MRI  Magnetic resonance imaging
mp-MRI  Multiparametric MRI
PCa  Prostate cancer
PSA  Prostate specific antigen
PZ  Peripheral zone
QoL  Quality of life
SE  Spin echo
SNR  Signal-to-noise ratio
T1w  T1-weighted imaging
T2w  T2-weighted imaging
TE  Echo time
TR  Repetition time
TRUFI  True fast imaging
TRUS  Transrectal ultrasound
TSE  Turbo spin echo
TZ  Transition zone
UTE  Ultrashort echo time
VIBE  Volume interpolated breath-hold examination


section 1
INTRODUCTION

GENERAL INTRODUCTION, 
THESIS AIM AND OUTLINE
chapter 1
12
CHAPTER 1
INTRODUCTION
THE PROSTATE GLAND
The prostate is a small exocrine gland of the male reproducti ve system and has approximately 
the size of a walnut. Its nomenclature is derived from the Greek word ‘prostates’, which 
means ‘one standing in front’ and refers to its locati on at the base of the urinary bladder, 
surrounding the proximal urethra and ejaculatory ducts before these structures unite at the 
verumontanum and reach the urethral opening (Fig 1a). Posteriorly, the prostate is located 
directly in front of the rectum.
 The main functi on of the prostate is to secrete prostati c fl uid which consti tutes about 15-
30% of the semen together with spermatozoa and seminal vesicle fl uid1. The smooth muscles 
in the prostate help expel the semen during ejaculati on. Anatomically, the prostate consists 
of three main zones: the peripheral zone, the central zone and the transiti on zone (Fig 1b).
The prostate mostly becomes of clinical signifi cance in elder men. With increasing age, the transiti on 
zone starts to enlarge in a non-malignant process called benign prostati c hyperplasia (BPH). BPH is 
characterized by the formati on of discrete, fairly large nodules in the transiti on zone. These nodules 
can compress the prostati c urethra, leading to urinary outf low obstructi on and voiding problems. 
Furthermore, cancer of the prostate can develop when glandular cells turn malignant and start to 
grow uncontrollably. This is called adenocarcinoma of the prostate, or prostate cancer. Prostate 
cancer predominantly occurs in the peripheral zone of the gland (70-80%)2,3.
Fig. 1 (a) Anatomical location of the prostate in the body. (b) Zonal anatomy of the prostate.
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PROSTATE CANCER
Prostate cancer (PCa) presents a signifi cant health problem in developed countries and is 
the second most common cancer diagnosed in men worldwide4. The disease accounted for 
an esti mated 19% (10.497) of all new cancer cases in males in the Netherlands in 20155. The 
incidence of prostate cancer has been increasing over the last decades, largely due to aging 
of the populati on and the advent of prostate specifi c anti gen (PSA) blood tests6,7. However, 
not all prostate cancers are aggressive and of men diagnosed with prostate cancer most will 
die with rather than from the disease8.
 In clinical practi ce, an elevated serum PSA or abnormal fi ndings on digital rectal examinati on 
(DRE) are commonly the initi al indicators raising suspicion of prostate cancer. However, since 
both tests have limitati ons in diagnosti c accuracy the current standard to diagnose prostate 
cancer is transrectal ultrasound (TRUS)-guided biopsy. Typically, a biopsy scheme of six to 
twelve cores is used to systemati cally sample the prostate (Fig. 2). The obtained ti ssue samples 
are subsequently evaluated by a pathologist to determine the presence of prostate cancer. 
If cancer is found, a Gleason score will be assigned, with higher scores indicati ng increased 
tumor aggressiveness9–11.
Accurate determinati on of tumor aggressiveness plays an important role towards determining 
the opti mal management. Some low aggressive or indolent forms of prostate cancer oft en 
grow slowly and may not require acti ve treatment. In these pati ents, careful monitoring 
by acti ve surveillance is considered an appropriate strategy13,14. More aggressive tumors or 
Fig. 2 (a) Schematic representation of the various sampling schemes and (b) typical needle trajectories 
used during TRUS-guided prostate biopsy, as presented by Harvey et al.12
a
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Accurate determination of tumor aggressiveness plays an important role towards 
determining the optimal management. Some low aggressive or indolent forms of prostate 
cancer often grow slowly and may not require active treatment. In these patients, careful 
monitoring by active surveillance is considered an appropriate strategy13,14. More aggressive 
tumors or advanced stage disease are an indication for active treatment15. Standard 
treatment options for localized prostate cancer are surgery (i.e. radical prostatectomy) or 
radiation therapy. Multiple studies have shown comparable overall survival and disease-free 
survival between both therapies and the best option has to be determined in each individual 
case, depending on patient and tumor characteristics16,17. Ultimately, also other factors such 
as age, general health and the patient’s views on each treatment and its side effects 
contribute to the final treatment choice. 
The current diagnostic and therapeutic pathways are not perfect. Diagnostically, 
assessment of the serum PSA has a high sensitivity but very low specificity and an increased 
PSA level could indicate prostate cancer but also be due to prostatic inflammation or 
BPH18,19. Likewise, a positive DRE has high specificity but sensitivity of the exam is low as 
small lesions or lesions located in the lateral or anterior aspects of the prostate cannot be 
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advanced stage disease are an indication for active treatment15. Standard treatment options 
for localized prostate cancer are surgery (i.e. radical prostatectomy) or radiation therapy. 
Multiple studies have shown comparable overall survival and disease-free survival between 
both therapies and the best option has to be determined in each individual case, depending 
on patient and tumor characteristics16,17. Ultimately, also other factors such as age, general 
health and the patient’s views on each treatment and its side effects contribute to the final 
treatment choice.
 The current diagnostic and therapeutic pathways are not perfect. Diagnostically, assessment 
of the serum PSA has a high sensitivity but very low specificity and an increased PSA level 
could indicate prostate cancer but also be due to prostatic inflammation or BPH18,19. Likewise, 
a positive DRE has high specificity but sensitivity of the exam is low as small lesions or lesions 
located in the lateral or anterior aspects of the prostate cannot be felt20. Also TRUS-guided 
biopsy is associated with a low sensitivity as a substantial proportion of prostate cancers may 
be missed, particularly in the anterior aspect of the prostate which is typically undersampled 
during TRUS biopsy. Furthermore, the technique has been shown to underestimate the 
Gleason score in 38-58% of cases21,22.
 The above inaccuracies have important implications for prostate cancer treatments. Due 
to the inability to precisely localize a tumor within the prostate, therapies have traditionally 
focused on treating the gland as a whole. Furthermore, discrepancies between the Gleason 
score found at TRUS biopsy and the true tumor aggressiveness may lead to undertreatment23,24. 
Alternatively, finding low-risk tumors on systematic biopsy can induce overtreatment and give 
rise to undesired side effects in men that may not benefit from active treatment25,26.
 These imperfections have fueled the search for an alternative diagnostic tool that can more 
accurately detect prostate cancer and provide improved localization and characterization of 
the disease towards optimizing treatment strategies.
15
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PROSTATE MRI
Magnetic resonance imaging (MRI) was introduced as a new medical imaging technique in 
the late 1970s. In MRI, the magnetic properties of protons are used to non-invasively acquire 
anatomical and functional information of tissues inside the human body. Since its introduction, 
the technique has found widespread application as a diagnostic tool in various pathologies.
 In the early 1980s, first urologic applications of MRI were explored and demonstrated 
the first in-vivo MR images of the prostate gland27,28. Further developments in the 1990s 
showed the capability of MRI to discriminate prostate cancer and the technique found early 
implementation in local staging of known cancers29–31. More recently, advancements in MRI 
technology, availability of systems with higher magnetic field strength and standardized 
imaging protocols have dramatically improved the diagnostic accuracy of prostate MRI. 
Fig. 3 Multiparametric MR images in a 83-year-old male with a PSA value of 10ng/ml. (a) Axial T2-weighted 
image depicts a hypointense lesion (red outline) in the right peripheral zone. (b) Axial ADC map and (c) 
DWI image with b = 1400 demonstrate an area of diffusion restriction and (d) axial DCE image shows focal 
enhancement corresponding to the lesion. Subsequent targeted biopsy showed a Gleason 5 + 4 = 9 prostate 
cancer. Adapted from Bomers et al.37
18 
 
techniques, such as diffusion-weighted imaging (DWI), dynamic contrast enhanced (DCE) 
imaging or MR spectroscopic imaging (MRSI), has shown incremental value in detecting PCa 
as compar  to anatomical imaging alone32–34 and recently publis d internati nal
guidelines strongly recommend the use of this multiparametric MRI (mpMRI) approach35,36 
(Fig. 2). 
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Over the last years, the clinical value of mpMRI to detect PCa has been well 
established38. Multiple studies have demonstrated high localization accuracy using this 
technique (AUC: 0.88-0.97)32,39, with a recent meta-analysis reporting a pooled sensitivity 
and specificity of respectively 0.74 and 0.8840. Besides detection of primary PCa, mpMRI has 
a b 
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A standard diagnostic prostate MRI examination consists of anatomical T2-weighted imaging in 
at least two or three orientations. The addition of one or more functional imaging techniques, 
such as diffusion-weighted imaging (DWI), dynamic contrast enhanced (DCE) imaging or MR 
spectroscopic imaging (MRSI), has shown incremental value in detecting PCa as compared 
to anatomical imaging alone32–34 and recently published international guidelines strongly 
recommend the use of this multiparametric MRI (mpMRI) approach35,36 (Fig. 3).
Over the last years, the clinical value of mpMRI to detect PCa has been well established38. 
Multiple studies have demonstrated high localization accuracy using this technique (AUC: 
0.88-0.97)32,39, with a recent meta-analysis reporting a pooled sensitivity and specificity of 
respectively 0.74 and 0.8840. Besides detection of primary PCa, mpMRI has also been shown 
to accurately detect PCa recurrence after previous radiotherapy41,42. Consequently, mpMRI 
has also been proposed in guiding prostate biopsies or treatment43.
MR-GUIDED PROSTATE BIOPSY
The ability of MRI to accurately detect and localize prostate cancer has initiated a shift in 
the concept of prostate biopsy. Now that regions within the prostate can be identified that 
are highly likely to harbor cancer, sampling can be targeted towards these suspicious areas.
Fig. 4 Schematic representation of MR-guided biopsy using an MR-compatible transrectal biopsy device. (a) 
Patient is positioned prone inside the scanner bore. (b) An MR-visible needle guide is inserted in the rectum, 
which can be directed to specifically target a cancer suspicious region within the prostate. Adapted from the 
information brochure “One-stop diagnosis of prostate cancer” of the Radboudumc.
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Technical developments in the early 00’s have led to the first systems for transrectal 
prostate biopsy that could be used inside the MRI scanner bore (Fig. 4) and resulted in 
several pioneering publications describing the feasibility of prostate biopsy under direct MR 
image-guidance (Fig. 5)44,45. 
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Technical developments in the early 00’s have led to the first systems for transrectal prostate 
biopsy that could be used inside the MRI scanner bore (Fig. 4) and resulted in several pioneering 
publications describing the feasibility of prostate biopsy under direct MR image-guidance (Fig. 5)44,45.
Initial results with in-bore MR-guided prostate biopsy in patients that had previously 
underwent TRUS-guided biopsy with negative findings were promising, with cancer detection 
rates up to 59%46 as compared to those traditionally reported for repeat TRUS biopsy (7-
17%)47–49. Recent studies have confirmed the high diagnostic performance of MR-guided 
prostate biopsy, demonstrating this biopsy technique to detect predominantly clinically 
Fig. 5 In-bore MR-guided prostate biopsy in a patient with clinical suspicion of prostate cancer and a cancer 
suspicious region on diagnostic prostate MRI located anteriorly in the left transition zone. (a) Axial and (b) 
sagittal MR images show positioning of the transrectal needle guide in line with the target lesion (red outline). 
The needle trajectory is indicated (white dotted line). (c) Axial and (d) sagittal MR images of subsequent core 
biopsy with the needle in situ (depicted by the linear hypointense needle artefact traversing the prostate)  to 
confirm appropriate sampling of the target lesion.
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Initial results with in-bore MR-guided prostate biopsy in patients that had previously 
underwent TRUS-guided biopsy with negative findings were promising, with cancer 
detectio  rates up to 59%46 as compared to those traditionally reported for repeat TRUS 
biopsy (7-17%)47–49. Recent studies have confirmed the high diagnostic performance of MR-
guided prostate biopsy, demonstrating this biopsy technique to detect predominantly 
clinically significant cancers (i.e. Gleason score 7 or higher)  with use of less biopsy cores 
compared to TRUS-guided biopsy50. 
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significant cancers (i.e. Gleason score 7 or higher)  with use of less biopsy cores compared 
to TRUS-guided biopsy50.
MR-GUIDED PROSTATE CRYOABLATION
Similar to the developments in prostate biopsy, the advent of MRI as an accurate tool to 
localize prostate tumors also enabled prostate treatment to be directed more towards the 
tumor focus instead of targeting the whole gland. Early applications of this approach were 
explored in radiotherapy, where an increased dose could be delivered to the area of the tumor 
without increased toxicity to the rest of the gland and surrounding structures51. More recently, 
there has been growing interest in focal ablative therapies, where only the tumor focus is 
locally treated while sparing as much adjacent healthy tissue as possible52,53. To date, several 
minimally invasive ablative techniques have been applied to PCa. Of these, cryoablation has 
had the longest history in the treatment of prostate tumors and is currently an established 
treatment option for clinically localized primary prostate cancer or local recurrence after 
primary radiotherapy (RT)54.
 Cryoablation is the in situ destruction of tissue by application of extreme cold to induce 
cell kill55. Direct tissue injury occurs mainly by cellular dehydration due to freezing of the 
extracellular water. This results in an osmotic gradient and fluid efflux, causing cell shrinkage 
and disruption of the cell’s integrity. This process is enhanced by the subsequent formation 
of intracellular ice crystals, inducing further injury to the organelles and the cell membrane. 
Indirect mechanisms of cold-induced tissue injury occur through vascular effects (i.e. 
endothelial damage leading to microthrombosis) and resulting ischemia.
 Traditionally, prostate cryoablation is applied in a whole-gland approach. In a typical 
procedure, several cryoprobes are transperineally inserted into the prostate under transrectal 
ultrasound guidance56,57. Transrectal ultrasound assists in probe placement and allows real-
time visualization of the ice-ball formation. Due to acoustic shadowing however, monitoring 
of the cryoablation ice-ball is limited to the proximal edge of the freezing front. As the full 
extent of the ablation zone remains unknown, unwanted freezing can occur of nearby at-risk 
structures, such as the rectal wall or neurovascular bundles, which may lead to treatment-
related complications.
 Nowadays, several groups have been exploring the use of MRI to guide prostate cryoablation 
procedures. MRI allows excellent depiction of the ablation zone with sharp contrast between 
frozen and non-frozen tissue58. Also, it enables assessment of the full extent of the cryoablation 
ice-ball in three dimensions (Fig. 6). Two recent studies have described initial experience 
with whole-gland prostate cryoablation under MR-guidance in patients with primary PCa or 
recurrence after radiotherapy or prostatectomy59,60.
19
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 At the same time, efforts have been made to explore the possibilities of partial or focal 
cryoablation, with the aim of reducing the morbidity associated with whole-gland treatment61. 
Previous studies have reported promising oncological outcomes and reduced side-effects 
using TRUS-guided focal cryoablation in patients with unilateral primary PCa62–64 or local 
recurrence65–67. More recently, we have shown the feasibility and procedural safety of 
performing focal cryoablation under MR-guidance in ten patients with locally recurrent PCa 
after primary RT, with encouraging initial results68.
Fig. 6 MR-guided cryoablation in a patient with locally recurrent prostate cancer in the left peripheral zone 
after primary radiotherapy. a) Axial and b) sagittal T1-weighted MR images show placement of four cryoprobes 
(blue circles) in the prostate (yellow outline) near the target area. C) Axial and d) sagittal T1-weighted MR images 
during cryoablation show the extent of the ice-ball (depicted by the hypointense signal void surrounding the four 
cryoprobes) after two 10-minute freeze cycles. A urethral warmer and rectal balloon are used to actively protect 
the urethra and rectum from freezing.
22 
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At the same time, efforts have been made to explore the possibilities of partial or 
focal cryoablation, with the aim of reducing the morbidity associated with whole-gland 
treatment61. Previous studies have reported promising oncological outcomes and reduced 
side-effects using TRUS-guided focal cryoablation in patients with unilateral primary PCa62–64 
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AIM AND OUTLINE OF THIS THESIS
MRI is currently the most accurate imaging modality to localize prostate cancer. Consequently, 
MRI poses a powerful tool to guide diagnostic and therapeutic prostate interventions. In this 
work, recent advances in MR-guided prostate interventions are presented. The general aim 
of this thesis is to evaluate and improve two MR-guided interventions: MR-guided biopsy 
for diagnosis and MR-guided cryoablation for focal treatment of (recurrent) prostate cancer.
The outline of this thesis consists of two parts. The first part evaluates the present status of 
MR-guided prostate biopsy and introduces a novel method to potentially accelerate these 
biopsy procedures. The second part explores the capabilities of MRI to monitor cryoablation 
and evaluates initial results with MR-guided focal cryoablation in patients with recurrent 
prostate cancer after radiotherapy.
Chapter 2 begins with a systematic review of the current clinical results of in-bore MR-guided 
prostate biopsy for the detection of prostate cancer. The strengths and present challenges of 
this biopsy technique are discussed.
In Chapter 3, a novel method to allow real-time targeting of cancer suspicious regions during 
in-bore MR-guided prostate biopsy is introduced. The clinical feasibility of this technique as 
well as the potential to accelerate the biopsy procedure is evaluated in patients.
Chapter 4 investigates the contrast around a cryoablation ice-ball in T1-weighted MR images. 
Observed signal changes are related to temperature in a phantom study and compared with 
its appearance during in vivo cryoablation in patients.
The feasibility of obtaining measurable MR signal from within frozen tissue using ultrashort 
echo time (UTE) MRI is demonstrated in an ex-vivo setting in Chapter 5. The accuracy of using 
the relative UTE signal to predict the three-dimensional temperature distribution inside a 
cryoablation ice-ball is investigated over the time course of a clinical cryoablation protocol.
Chapter 6 evaluates the initial results of MR-guided cryoablation in patients with local 
recurrent prostate cancer after initial radiotherapy. Technical feasibility of the technique and 
short-term follow-up on adverse events, quality of life (QoL) and local cancer control were 
assessed.
21
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In Chapter 7, preprocedural diagnostic and intraprocedural MR images are analyzed to 
evaluate the ice-ball margins achieved during MR-guided cryoablation of recurrent prostate 
tumors. Furthermore, it is investigated whether the derived ice-ball margins correlate with 
local outcome.
Chapter 8 provides a summary of this thesis, a general discussion of the results and future 
perspectives. In Chapter 9, a Dutch translation of the summary is provided.
22
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ABSTRACT
In-bore magnetic resonance-guided biopsy (MRGB) has been increasingly used in clinical 
practice to detect prostate cancer (PCa). This review summarizes the current clinical results 
of this biopsy method. A systematic literature search was performed in the PubMed and 
Embase databases. Of 2,035 identified records, 49 required full review. In all, ten unique 
studies reporting clinical results of MRGB could be included. Reported PCa detection rates 
ranged from 8 to 59 % (median 42 %). The majority of tumors detected by MRGB were clinically 
significant (81–93 %). Most frequent complications of MRGB are transient hematuria (1–24 
%) and short-term perirectal bleeding (11–17 %). Major complications are rare. Based on the 
reviewed literature, MRGB can be regarded an accurate and safe diagnostic tool to detect 
clinically significant PCa. However, as general availability is limited, this procedure should be 
reserved for specific patients. Appropriate indications will have to be determined.
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INTRODUCTION
Prostate cancer (PCa) continues to be a major health problem in developed countries, 
accounting for an estimated 29% (240,890) of new cancer cases and 11% (33,720) of cancers 
deaths in men in the United States in 20111. In the era of prostate specific antigen (PSA) 
screening tests, urologists are increasingly confronted with the dilemma of seeing patients 
with a high clinical suspicion of PCa but negative transrectal ultrasound (TRUS)-guided biopsy 
results. Additional biopsy sessions have no significant impact on cancer detection, leaving a 
large number of patients with diagnostic uncertainty2-4.
 Over the past years, the value of multi-parametric magnetic resonance imaging (MRI) in 
detecting PCa has been well established. Using this technique, high localization accuracy can 
be achieved (AUC 0.88-0.97)5,6. Consequently, MR imaging has also been proposed in guiding 
biopsies towards cancer suspicious regions, with the aim of improving diagnostic performance 
of prostate biopsy.
 Initial case reports describing MR-guided biopsy (MRGB) for PCa detection appeared 
in 20007,8. The first study on the clinical use of MRGB of the prostate in a patient cohort 
(n=12) originates from 2005, when Beyersdorff et al. reported the results of using a newly-
developed MR-compatible biopsy device in a transrectal approach within a closed-bore 1.5T 
MR-system9. Since then, several strategies to perform in-bore MR-guided prostate biopsy 
have been developed and applied clinically10.
 The purpose of this review is to summarize current clinical results of in-bore MRGB of the 
prostate for PCa detection.
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MATERIALS AND METHODS
A systematic literature search was performed. Articles published in English and before 
December 1, 2012 were retrieved from Pubmed (U.S. National Library of Medicine) and 
Embase online search engines. A combination of the following free search terms and Medical 
Subject Headings was used: MRI, MR-guided, image-guided, prostate, biopsy. Abstracts were 
reviewed for relevance to the research subject. If relevance was unclear from the abstract, 
the full-text paper was assessed. References cited in full-text articles were checked for 
additional relevant articles. Articles published before 2000 were excluded as MR-techniques 
and equipment have changed considerably since then. Ex vivo, in vitro and phantom studies 
were also excluded, as well as studies using robotic devices as this field is still relatively new 
and clinical applications are scarce (Fig. 1). All studies were scored: for each article, data on 
study design, patient population, biopsy approach, technical aspects of the procedure, PCa 
detection rate and adverse events were documented.
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RESULTS
In total, 10 reports describing clinical results of in-bore MR-guided prostate biopsy in separate 
patient populations could be included9,11-19. For these studies, PCa detection rates, complication 
rates and technical aspects of the biopsy procedure were listed (Table 1).
PATIENT CHARACTERISTICS
Patient populations in which MRGB has been evaluated ranged from 12 subjects in the 
initial study by Beyersdorff et al. to 265 subjects in the largest cohort by Hoeks et al. Most 
common inclusion criteria were an elevated PSA (>4 ng/ml) and/or a suspicious digital 
rectal examination (DRE) in combination with at least one (n=6) or two (n=1) negative TRUS-
guided biopsy (TRUSGB) sessions. In all studies, median patient age ranged from 61 to 68 
years and median PSA values at inclusion between 4.9 and 13.0 ng/ml. Median number of 
previous negative TRUSGB sessions ranged from 1 to 3. In all studies, MRGB was preceded 
by a diagnostic prostate MR examination. Diagnostic MR imaging was mostly performed 
using an endorectal coil and comprised at minimum of T2-weighted anatomical imaging in 
two orthogonal orientations. In most cases however, this was supplemented by at least one 
(n=1) or multiple (n=4) functional imaging techniques, i.e. diffusion-weighted (DWI), dynamic 
contrast-enhanced (DCE) or spectroscopic imaging. The median time between diagnostic MRI 
and MRGB ranged from 0.5 to 8 weeks.
BIOPSY PROCEDURE
MRGB is most commonly performed on closed-bore MR systems (n=9), operating at either 
1.5T or 3.0T field strength. In the closed-bore setting, all studies utilized a transrectal approach. 
One paper reported on MR-guided prostate biopsy via a transgluteal pathway. This study was 
performed in an open-bore interventional system using free-hand needle insertion. In all 
other studies, either a commercially available biopsy device (DynaTRIM®, Invivo, Schwerin, 
Germany) or an in-house developed assistance device was used for needle guidance. The 
most common patient position was prone (n=6). In all studies, non real-time intraprocedural 
imaging was performed to control needle targeting. Most used sequences were the balanced 
steady state free precession (bSSFP) (n=3) or T2w turbo spin echo (TSE) (n=3). Depending on 
approach and biopsy technique, median procedure times for the biopsy procedure ranged 
from 19-68 minutes. When MRGB was performed transrectally, antibiotic prophylaxis was 
given with ciprofloxacin (n=7) or fluoroquinolones (n=1).
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CLINICAL RESULTS
Reported PCa detection rates for MRGB ranged from 8-59% (median 42%) (Table 1). Of all 
tumors detected by MRGB, 81-93% were clinically significant. The most frequent major 
complications of MRGB were urosepsis (0-2%) and urinary retention (1%). Common minor 
complications were transient hematuria (1-24%) and short-term perirectal bleeding (11-17%).
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DISCUSSION
In patients with a set of initial negative transrectal ultrasound-guided prostate biopsies and 
persisting clinical suspicion of prostate cancer, additional TRUS-guided biopsy rounds or, 
eventually, saturation biopsy are the current standard of care20,21. Reported PCa detection 
rates for repeat TRUSGB are in the order of 7–17%2-4,22,23. In the present literature, cancer 
detection rates reported for in-bore MR-guided prostate biopsy in similar patient groups are 
markedly higher (up to 59%). Also, MRGB has been shown to detect predominantly clinically 
significant cancers.
 At the same time, the complications reported for MRGB are comparable to those associated 
with TRUSGB. For both techniques, minor complications, such as transient hematuria or 
short-term perirectal bleeding, may be observed commonly while major complications 
are rare24,25. Hence, MR-guided biopsy for PCa detection can be regarded to achieve high 
diagnostic performance at similar complication rates.
 The high diagnostic performance of MRGB may be the direct result of two unique 
advantages. First, MRGB is usually performed with the precondition of a preceding positive 
diagnostic prostate MR examination. As prostate MR imaging has been associated with high 
PCa localization accuracy, biopsies can be targeted directly onto those regions most likely to 
harbor prostate cancer. In addition, also the proportion of tumors (20-25%) located in the 
ventral aspects of the prostate, outside of the areas usually sampled with TRUSGB, may be 
accurately targeted with MRGB 26-28. Consequently, reported missed cancer rates of MRGB 
are low (6-10%)11,16,17. Second, MR image guidance during the biopsy procedure itself may 
help to ensure that designated lesions are sampled correctly. In a study by Hambrock et al., 
specimens obtained by MRGB were found to be highly representative of true tumor grade, 
exactly matching prostatectomy histopathology in 88% of cases29. This is in sharp contrast with 
TRUSGB, in which undergrading represents a significant issue reported to occur in 44-60% 
and 32-38% of cases for standard sextant and extended biopsy respectively30-32.
 One of the main concerns for MRGB however, is that procedures can be time consuming. 
Shortest median procedure time reported (19 min.) could be achieved when biopsy was 
performed in an interventional open-bore MR system. However, due to the restricted diagnostic 
imaging capabilities of these low-field systems, MRGB is mostly performed on closed-bore 
systems. In closed-bore scanners, workspace is limited though and needle guidance devices 
are often used to ensure accurate biopsy. To facilitate needle guide adjustments, patients may 
be slid in and out of the scanner several times during the procedure. In turn, this is followed by 
short imaging steps in order to assess the current needle guide orientation. This cycle has to 
be repeated until the needle guide is pointing at the desired target area. Only then, the actual 
biopsy can be performed. In some needle guidance solutions, included software can be used 
to derive a rough estimation of the correct device orientation to target a given lesion. In that 
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case, only fine-tuning of the needle guide position is required, potentially speeding up the 
targeting process. Still, reported median procedure times for MRGB in a closed-bore setting 
(30-68 min.) are substantially longer than those usually required for TRUSGB33. To address this 
problem, the concept of MR-compatible robotics was proposed. Robotic devices may be used 
to remotely steer a needle guide towards a target lesion from outside the scanner room. In this 
way, manipulation time may be greatly reduced. Recently, several studies have demonstrated 
the feasibility of robotic assisted in-bore MR-guided prostate biopsy, with promising initial 
results34,35. However, clinical applications of these techniques are still scarce and the actual 
value of these techniques is yet to be determined36.
 Another issue of MRGB is the limited general availability. MRGB is still a relatively new 
technique. In addition, MRGB can be a costly procedure, requiring special, MR-compatible 
equipment. Also, site-experience with prostate MR imaging as well as trained radiologists in 
this field are a prerequisite.
 Due to these restrictions, at this time, MRGB should be reserved for specific patients. 
Potential indications may include MR-imaging identified lesions that are either very small or 
located in areas difficult to reach with standard TRUSGB or cases of a discrepancy between 
imaging findings and histopathology. In the future, MR/TRUS-fusion guided biopsy may pose 
a promising alternative to overcome this problem37-39. By registering prior prostate MR images 
to live transrectal ultrasound imaging, the strengths of diagnostic MR imaging can be brought 
to urologist’s office and targeted biopsy strategies may become more widely available.
37
MRI-GUIDED BIOPSY FOR PROSTATE CANCER DETECTION
CONCLUSION
Based on current clinical results, in-bore MR-guided prostate biopsy can be regarded an 
accurate and safe diagnostic tool to detect clinically significant PCa in patients with previous 
negative TRUS-guided biopsies. As general availability of the technique is limited though, 
this procedure should be reserved for specific patients. Appropriate indications will to have 
to be determined.
Fig. 1 Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) flow diagram describing 
the results of the systematic literature search and additional selection based on exclusion criteria.
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FIGURES
Table 1 Current clinical results and technical aspects of in-bore MR-guided prostate biopsy
Tabellen – chapter 2 
Table 1.  li i l l   technical aspects of in-bore MR-guided prostate biopsy 
Authors Year Subjects MR-system Approach PCa 
detection 
rate 
CSD Complications Procedure 
time (min) 
          
Beyersdorff et al. (9) 2005 12 Closed 1.5T Transrectal 42% (5/12) NA None reported 55 (40-60) 
Zangos et al. (11) 2005 25 Open 0.2T Transgluteal 40% (10/25) NA Transient hematuria (8%) 19 (14-35) 
Anastasiadis et al. (12) 2006 26 Closed 1.5T Transrectal 58% (15/26) NA Perirectal hemorrhage 
(11%) 
68 (30-90) 
Singh et al. (13) 2008 13 Closed 3.0T Transrectal 8% (1/13) NA NA 100 (80-185)* 
Hambrock et al. (14) 2010 68 Closed 3.0T Transrectal 59% (40/68) 93% Transient hematuria (1%) 
Urinary tract infection (1%) 
30 (14-75) 
Franiel et al. (15) 2011 54 Closed 1.5T Transrectal 39% (21/54) NA NA 55 (34-80) 
Engehausen et al. (16) 2012 96 Closed 1.0/1.5T Transrectal 41% (39/96) NA Urinary retention (1%) 
Transient hematuria (24%) 
Perirectal hemorrhage 
(17%) 
NA (40-60) 
Hoeks et al. (17) 2012 265 Closed 3.0T Transrectal 41% 
(108/265) 
87% Urosepsis (0.4%) 
Vasovagal (1.5%) 
44 (35-51) 
Roethke et al. (18) 2012 100 Closed 1.5T Transrectal 52% 
(52/100) 
81% NA 48 (28-95) 
Schwab et al. (19) 2012 50 Closed 1.5/3.0T Transrectal 50% (25/50) NA Urosepsis (2%) NA 
          
 
CSD = clinically significant disease, NA = not available, * = including diagnostic MR imaging. 
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ABSTRACT
PURPOSE
To assess the feasibility of real-time targeting during transrectal 3-T in-bore magnetic 
resonance (MR)-guided prostate biopsy.
MATERIALS AND METHODS
For this institutional review board-approved study, twenty patients with one cancer suspicious 
region (CSR) with PI-RADS score ≥4 on diagnostic multiparametric MRI were prospectively 
enrolled. After CSR-reidentification, two orthogonal scan planes of an interactive real-time 
sequence (~3 imgs/s) were aligned to the target lesion and pivoting point of a commercially-
available transrectal needle guide using planning software. Targeting of a CSR was achieved by 
positioning the needle guide into the planned scan planes under real-time MR image guidance 
displayed on a tablet device in the scanner room. Technical feasibility and targeting success 
were assessed. A matched cohort (n=31) that underwent routine MR-guided prostate biopsy 
was retrospectively retrieved from our institutional database as reference. Statistical analysis 
was performed to evaluate biopsy times between groups.
RESULTS
Real-time targeting was technically successful in all patients and allowed sampling of each 
CSR (median size 14 mm, range: 4-45) without requiring additional needle guide adjustment 
in all but one patient (19/20 lesions; 95%). Biopsy cores contained cancer in 18/20 patients. 
With real-time targeting, mean time to first biopsy was 49% (5.8±1.0 vs. 11.4±4.7 min; P<.001) 
and mean total procedure time 30% (23.7±4.1 vs. 33.9±7.5 min; P<.001) reduced compared 
to the reference cohort.
CONCLUSION
Real-time targeting was feasible during transrectal 3-T in-bore MR-guided prostate biopsy. 
Our initial clinical experience indicates a substantial reduction of procedure time compared 
to the current biopsy procedure.
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INTRODUCTION
Prostate cancer (PCa) is the most common non-cutaneous cancer diagnosed in men in 
developed countries, with an estimated 220,000 new cases in the United States in 20151. 
Transrectal ultrasound (TRUS)-guided biopsy is the current standard technique to detect PCa, 
but has limited sensitivity and false-negative rates up to 32% have been reported for initial 
biopsy with six to twelve-core systematic biopsy schemes2,3. Repeated biopsy sessions have 
shown little impact on cancer detection4,5.
 In recent years, multi-parametric magnetic resonance (MR) imaging has evolved towards a 
mature imaging modality to detect PCa with high localization accuracy6,7. Consequently, MR 
imaging (MRI) has been proposed in targeting biopsies towards cancer suspicious regions 
(CSR) and several studies have demonstrated high diagnostic performance (detection rates 
45-59%) using in-bore MR-guided prostate biopsy in patients with initial negative TRUS 
biopsy8–10. Nevertheless, an important concern for in-bore biopsy is that a substantial part of 
the procedure is taken up by repeated needle guide adjustments requiring the physician to 
walk in and out of the MR-scanner room11 and typical procedure times have been considerably 
longer than those of TRUS-guided biopsy12.
 To improve the current workflow, we propose a method for real-time targeting using 
interventional planning software and a tablet device in the MR-room. By performing the 
targeting process under real-time MR image guidance, this approach may eliminate the need 
for repeated needle guide adjustments and could potentially accelerate in-bore prostate 
biopsy procedures. The purpose of the present study was to assess the feasibility of real-
time targeting on a tablet device during transrectal 3-T in-bore MR-guided prostate biopsy.
48
CHAPTER 3
MATERIALS AND METHODS
PATIENT POPULATION
For this institutional review board (IRB)-approved feasibility study, 20 males scheduled for MR-
guided prostate biopsy with one CSR with a PI-RADS13 score ≥4 on diagnostic multi-parametric 
prostate MRI (mpMRI) were prospectively enrolled between June and October 2016. All 
biopsy procedures were performed on a 3-T clinical MR system (MAGNETOM Skyra, Siemens, 
Erlangen, Germany) by one prostate interventionalist (C.O., 4-yr experience). Informed 
consent was obtained from all patients.
 Additionally, a cohort (n=31) that underwent current routine MR-guided prostate biopsy 
performed by the same prostate interventionalist between January 2014 and March 2016 
and matching the inclusion criteria (i.e. one CSR with PI-RADS score ≥4) was retrospectively 
retrieved from our institutional database as a reference.
 A summary of patient demographics and characteristics of biopsied lesions is given in 
Table 1.
CURRENT MR-GUIDED BIOPSY ROUTINE
Patient preparation, antibiotic prophylaxis and workflow of the current MR-guided prostate 
biopsy routine have previously been in detail11. In brief, axial T2-weighted turbo spin echo 
(T2-TSE) and diffusion-weighted imaging (DWI) were acquired to reproduce pre-biopsy MRI 
findings. A commercially available transrectal biopsy device (DynaTrim, Invivo, Gainesville, 
Florida, US) was used to target CSRs. Needle guide manipulation was performed iteratively, 
interleaved by short balanced steady-state free precession (bSSFP) imaging steps. Upon 
correct alignment, sampling was performed using an 18-gauge fully automatic MR-compatible 
biopsy gun (Invivo, Gainesville, Florida, US). Axial and sagittal bSSFP confirmation scans were 
acquired with the needle in situ to map each biopsy location.
REAL-TIME TARGETING
For the proposed real-time targeting method, a tablet device was installed in the MR-room. 
This tablet device was connected to a stand-alone computer outside the scanner room via 
a remote desktop application (VNC Viewer, RealVNC, Cambridge, UK) on a secured wireless 
network connection (Figure 1). A schematic overview of the biopsy procedure with real-
time targeting is shown in Figure 2. Routine axial T2-TSE and DWI imaging were acquired to 
re-identify the CSR. An additional axial T2-TSE dataset with extended slices incorporating 
the entire needle guide was acquired for planning purposes. On the stand-alone computer 
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Interactive Front End (IFE) software (Siemens Healthcare GmbH, Erlangen, Germany) was used 
to identify two points in the planning image set: (i) the biopsy target and (ii) the needle guide 
pivoting point (Figure 3). Two orthogonal MR scan planes were aligned to these points in axial 
and sagittal orientation such that each imaging slice intersected both the target and pivoting 
point and corresponded to one of the degrees of freedom of the biopsy device (i.e. either 
left-right or cranio-caudal rotation). The scan planes were returned to the scanner console, 
providing the slice positions for an interactive real-time balanced steady-state free precession 
(BEAT) sequence (temporal resolution ~3 imgs/s). The interventionalist then entered the 
MR-room and targeted the CSR by positioning the needle guide into both scan planes under 
real-time MR image guidance visualized on the tablet device (iPad 2, Apple, California, USA) 
(Figure 4). Upon completion, fast bSSFP scans were performed in axial and sagittal orientation 
to assess whether the needle guide was correctly aligned with the CSR. In case of satisfactory 
alignment, biopsy was performed. When the alignment was insufficient, additional manual 
adjustments were performed before the biopsy was taken. Routine axial and sagittal bSSFP 
confirmation scans were obtained directly after each biopsy to map the biopsy location. 
Detailed imaging parameters of the biopsy procedure are summarized in Table 2.
 After the procedures, all biopsy samples underwent histopathological work-up with 
hematoxylin-eosin staining and were subsequently evaluated for the presence of PCa or 
benign findings. When applicable, a Gleason score was assigned.
MR SAFETY
Prior to IRB-application for this study, the magnetically induced displacement force on the 
tablet device was determined following American Society for Testing of Materials (ASTM) 
standard test methods14. The tablet device was attached to a non-magnetic fixture using a 
nylon string such that it hang free in space. Using a protractor with 1° graduated markings 
the deflection angle due to magnetic attraction of the tablet device was measured at multiple 
locations in the scanner room. For the specified tablet and under the studied circumstances at 
3-T, it was found that the unfixed device could be safely operated at 50 cm from the bore entry 
without significant magnetic attraction (i.e. deflection angle <45°). During all procedures, the 
tablet device was never operated at any distance smaller than this iso-distance. To prevent 
any chance of accidental magnetic attraction, the tablet device was incorporated into a 
perspex holder mounted to a non-magnetic fixture which was secured to the MR scanner 
table. Finally, additional ASTM safety tests15 were conducted to establish whether the tablet 
device or wireless network connection affected MR image quality. No noticeable interferences 
or artefacts were recorded.
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TARGETING SUCCESS AND BIOPSY TIMES
Technical feasibility and targeting success of real-time lesion targeting were assessed. Targeting 
success was defined as obtainment of a representative biopsy core after final alignment under 
real-time imaging without requiring additional needle guide adjustment. Representativity 
of each biopsy core was indicated on a five-point scale (i.e. 1 = not representative to 5 = 
representative) by the prostate radiologist reviewing the confirmation scan of the biopsy, 
where a score of ≥4 was considered a representative sample.
 Biopsy procedure times were also recorded. The time to first biopsy was defined as the time 
between acquisition of DW imaging and the confirmation scan of the first biopsy. The total 
procedure time was defined as the time between localizer acquisition and the last scan of the 
biopsy procedure. Finally, the manipulation time for real-time targeting was defined as the 
time required to align the needle guide to the CSR under real-time imaging. The set-up time 
was not recorded. Installation of the required hardware had to be performed once (approx. 
5-10 minutes). After installation, the setup could be used for multiple biopsy procedures on 
the same day without requiring additional set-up time between patients.
STATISTICAL ANALYSIS
Statistics were performed using SPSS (Version 20.0). Demographic data and procedure 
times were compared between both groups using independent samples T-test for normally 
distributed and Mann-Whitney U-test for non-normally distributed data. Chi-square analysis 
was used for discrete data. P-values <.05 were considered statistically significant.
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RESULTS
REAL-TIME TARGETING
A total of 20 CSRs were successfully sampled in twenty patients. A median of two biopsy 
cores (range: 2-3) were taken per CSR and a total of 46 biopsy samples were obtained. No 
per-procedural complications occurred. There were no post-biopsy complications recorded 
in terms of severe pain, bleeding or infection.
 Real-time targeting was technically feasible in all patients without experiencing 
interferences or image artefacts due to the presence of the tablet device inside the MR-room. 
Targeting success was achieved in all but one patient (19/20 lesions; 95%). In one patient, an 
additional adjustment step was needed because the lesion was located anteriorly outside 
of the maximum range of the needle guide. After forward adjustment of the needle guide, 
biopsy could be performed successfully. Median radiological score of biopsy representativity 
was 5/5 (range: 4-5).
HISTOPATHOLOGIC FINDINGS
Histopathology showed prostate cancer in 18/20 (90%) patients. Gleason scores were 3+3 
(3), 3+4 (10), 3+5 (1), 4+3 (2), 4+4 (1) and 4+5 (1). In total, 42 of 46 (91%) biopsy samples 
contained cancer. In two patients (10%), biopsy samples contained prostatitis.
BIOPSY AND PROCEDURE TIMES
With real-time targeting, the mean time to first biopsy was 5.8±1.0 min. and the mean total 
procedure was 23.7±4.1 min. The mean manipulation time to align the needle guide to a CSR 
was 1.1±0.3 min.
 In the reference cohort, mean time to first biopsy and mean total procedure time were 
11.4±4.7 min and 33.9±7.5 min respectively. On average, time to first biopsy was 5.6 min. 
(49%; P<.001) reduced and total procedure time 10.2 min. (30%; P<.001) reduced compared 
to the routine biopsy procedure. There were no significant differences in pre-biopsy patient 
and lesion characteristics between the real-time targeting and reference cohort. A comparable 
number of biopsy cores was obtained per patient in both groups (P=.22).
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DISCUSSION
This work described a method for real-time targeting during in-bore MR-guided prostate 
biopsy and demonstrated its feasibility in patients. Biopsy samples could be successfully 
obtained from each CSR, without requiring additional needle guide adjustment in all but 
one patient. Initial clinical findings show a substantial reduction of biopsy procedure time.
 In an effort to reduce procedure times of in-bore MR-guided prostate biopsy, alternative 
solutions have previously been proposed by others. Several groups have developed MR-
compatible robotics to aid in in-bore prostate biopsy16–18, of which some were also tested in 
the clinic19,20. Although these studies have demonstrated the feasibility of robotically-assisted 
prostate biopsy in small patient groups, a recent review concluded that the exact value of 
these techniques remains to be established with more clinical data being needed21. Another 
report has described an algorithm for automated phase-only cross correlation (POCC)-based 
needle-guide tracking to facilitate fast targeting of CSRs22. Another alternative to displaying 
the real-time images on the tablet device would be to use an MR-compatible display screen. 
With respect to some of these other solutions, the proposed method in this work is a 
relatively simple one. Also, minimal additional hardware or equipment costs (i.e. a tablet 
device and wireless network connection) are required, which could be an advantage towards 
implementation in the clinic.
 A significant reduction in biopsy procedure times was observed using the real-time 
targeting approach in comparison to that in patients who underwent the current routine 
biopsy procedure. Even though an additional ~2 min. of scanning time required to obtain the 
T2-TSE planning data set were included into our study protocol, the last ten procedures were 
all performed in less than 25 minutes. Compared to median procedure times of transrectal 
in-bore MR-guided prostate biopsy reported in the literature (30-68 minutes)12, this presents 
a considerable time improvement. More recently, a study has described initial results of 
transrectal MR-guided prostate biopsy with a robotic manipulator and achieved biopsy of one 
CSR per patient in a median procedure time of 37 minutes (range: 23-61)19. Another study 
used a needle guide tracking sequence to biopsy a median of two CSRs (range: 1-4) per patient 
in a median of 32 minutes (range: 14-48), however the time needed for diagnostic scans to 
re-identify CSRs was not included in this procedure time.
 Some factors may still be optimized about the real-time targeting process. The incorporation 
of a single T2-TSE sequence that can be used both for CSR-reidentification as well as planning 
of the needle guide trajectory could obviate the need for an additional planning data set. Also, 
optimization of the planning software or integration with the scanner platform could improve 
the workflow and allow further acceleration of the biopsy procedure.
 Our cancer detection rate (90%) was considerably higher than that reported in other studies 
of MR-guided prostate biopsy8–10,23. Most likely this is caused by the inclusion of only CSRs with 
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a PI-RADS score ≥4, with higher PI-RADS scores corresponding to an increased likelihood of 
prostate cancer presence24,25. Also, eight of 20 patients (40%) had a prior diagnosis of minimal 
low-risk PCa on TRUS-guided biopsy. These patients presented with a PI-RADS ≥4 lesion on 
diagnostic mpMRI performed as part of their active surveillance protocol. Nevertheless, the 
finding of a high prostate cancer yield in itself seems a confirmation that CSRs were adequately 
sampled using the real-time targeting technique.
 One issue with the current proposed approach is that real-time MR guidance comes with 
the prerequisite of manipulating the needle guide close to the center of the bore while the 
patient is on the scanner table. Potentially, some performing physicians may be unable to 
reach the needle guide inside the magnet, particularly in long bore MR-systems or when 
access to the biopsy device may be blocked due to the patient. Also, the real-time targeting 
method is presently only compatible with transrectal biopsy using a specific commercial biopsy 
device in combination with interventional planning software of one vendor. Finally, the results 
of this feasibility study need to be confirmed in a larger population and in biopsy procedures 
where multiple CSRs are targeted per patient. In addition, MR/TRUS fusion-guided biopsy is 
another biopsy approach that is rapidly gaining clinical acceptance as a possible alternative to 
in-bore prostate biopsy26,27. More data concerning procedure times of this biopsy technique 
are needed and when available these should be included in future comparisons.
 In conclusion, real-time targeting was feasible during transrectal 3-T in-bore MR-guided 
prostate biopsy. Our initial clinical experience indicates a substantial reduction in procedure 
times compared to the current biopsy procedure, which could be of value to increase clinical 
applicability of in-bore prostate biopsy.
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FIGURES
Fig 1 A, Diagram illustrates the setup for real-time targeting. The MR console is connected to a stand-alone 
computer running IFE planning software. The tablet device in the MR-room is connected to the stand-alone 
computer via a remote desktop application over a secured wireless network connection to allow direct 
visualization of real-time MR images in the scanner room. B, Photograph shows the setup of the tablet device in 
the MR-room.
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Fig 1. A, Diagram illustrates the setup for real-time targeting. The MR console is connected to a stand-alone 
computer running IFE planning software. The tabl t device in the MR-room is conn cted to the stan -alone 
computer via a remote desktop application over a secured wireless network connection to allow direct 
visualization of real-time MR images in the scanner room. B, Photograph shows the setup of the tablet device 
in the MR-room. 
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Fig 2 Schematic overview of procedure steps for the current routine and real-time targeting biopsy procedure.
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Fig 2. Schematic overview of procedure steps for the current routine and real-time targeting biopsy procedure. 
  
Fig 3 Overview of the IFE planning module shows a multiplanar reconstruction of the T2-TSE planning images. 
In the software, the biopsy target (pink) and pivoting point of the transrectal needle guide (green) can be 
selected. A planned trajectory through these points is automatically calculated (yellow path). Two imaging slices 
are then manually aligned to this trajectory such that their orientations are only rotated in one plane, i.e. either 
transverse or sagittal rotation. The planned scan planes are sent back to the MR console, providing the slice 
position for a real-time imaging sequence.
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Fig 3. Overview of the IFE planning module shows a multiplanar reconstruction of the T2-TSE planning images. 
In the software, the biopsy target (pink) and pivoting point of the transrectal needle guide (green) can be 
selected. A planned trajectory through these points is automatically calculated (yellow path). Two imaging 
slices are then manually aligned to this trajectory such that their orientations are only rotated in one plane, i.e. 
either transverse or sagittal rotation. The planned scan planes are sent back to the MR console, providing the 
slice position for a real-time imaging sequence. 
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Fig 4 Images in a 63-year old man with elevated PSA. A, Axial diagnostic T2-weighted and B, DW imaging (high 
b-value image; 1400 s/mm2) show a focal hypointense lesion with diffusion restriction (white outline) suspicious 
for PCa in the left peripheral zone. C, Axial and D, sagittal view of the needle guide trajectory obtained after 
planning in the IFE software. E, Axial and F, sagittal BEAT images aligned to the planned trajectory show the final 
needle guide position after real-time targeting. G, Axial and H, sagittal fast bSSFP scans confirm correct alignment 
of the needle guide with the CSR in both orientations (yellow dotted lines). Subsequent biopsy 
showed a Gleason 3+4=7.
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Fig 4. Images in a 63-year old man with elevated PSA. A, Axial diagnostic T2-weighted and B, DW imaging (high 
b-value image; 1400 s/mm2) show a focal hypointense lesion with diffusion restriction (white outline) 
suspicious for PCa in the left peripheral zone. C, Axial and D, sagittal view of the needle guide trajectory 
obtained after planning in the IFE software. E, Axial and F, sagittal BEAT images aligned to the planned 
trajectory show the final needle guide position after real-time targeting. G, Axial and H, sagittal fast bSSFP 
scans confirm correct alignment of the needle guide with the CSR in both orientations (yellow dotted lines). 
Subsequent biopsy showed a Gleason 3+4=7. 
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TABLES
Table 1 Patient and lesion characteristics, median or mean (range) or n (%).
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Table 1 – Patient and lesion characteristics, median or mean (range) or n (%). 
 Real-time targeting 
cohort 
(n=20) 
Reference 
cohort 
(n=31) 
P-value 
    
Patient age (y) 63 (54–78) 66 (51–73) 0.76 
PSA level (ng/mL) 14.9 (4.8–48.1) 11.5 (1.4–30) 0.22 
Previous negative TRUS-guided biopsy 
sessions 
3 (0–7) 1 (1–8) 0.08 
PSA density 0.31 (0.09–0.93) 0.20 (0.02–0.44) 0.10 
Lesion localization    
peripheral zone 14 (70) 16 (53)  
transition zone 6 (30) 14 (47)  
Lesion suspicion score    
PI-RADS 4 10 (50) 12 (40)  
PI-RADS 5 10 (50) 18 (60)  
Lesion size (mm) 14 (4–45) 15 (6–26) 0.66 
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CHAPTER 4
ABSTRACT
PURPOSE
To correlate T1-weighted (T1w) MR image contrast around a cryoablation ice-ball with 
temperature in a phantom study and to compare this to its in vivo appearance during MR-
guided focal cryoablation of prostate cancer.
METHODS
An MR-compatible cryoneedle was inserted into identical gel phantoms (n=3) on a 1.5T MR 
system. Two fiberoptic temperature sensors were placed parallel to the needle. A fast 3D 
T1w gradient echo (GRE) sequence (TR/TE/FA=4.81/1.98/6°) was used to monitor ice-ball 
progression. Normalized signal intensity (SI) was correlated with temperature. The same T1w 
sequence was used during MR-guided prostate cryoablation in 10 consecutive patients at our 
institution. In vivo findings were quantitatively compared to the phantom data.
RESULTS
In the phantom study, the cryoablation ice-ball appeared in the T1w MR images as a sharply 
delineated signal void. A 2.2±0.2 mm wide hyperintense rim directly surrounded the ice-ball 
at cooled but non-freezing temperatures (<20°C) in the gel. Normalized SI was maximum 
at 8.4±2.4°C, showing a 35.6-43.0% (mean 40.5%) increase with respect to baseline before 
cooling. In the clinical procedures, the same image contrast was observed in vivo in all patients. 
In vivo, width of the hyperintense rim was 1.6±0.6 mm. Normalized SI increases with respect to 
non-treated prostate ranged 28.4-55.6% (mean 36.8%). On quantitative analysis, normalized 
SI changes along a linear region of interest from surrounding tissue onto the ice-ball center 
were similar between the patients and phantom setting (root mean square difference 0.06).
CONCLUSIONS
The hyperintense rim around the ice-ball in fast T1w GRE images corresponded to cooled but 
non-freezing temperatures (<20°C) proximal to the frozen zone. The same image contrast was 
observed both in a phantom study as well as in vivo in the human prostate during cryotherapy. 
Potentially, monitoring of this rim could be useful in order to maintain a safe margin from 
at-risk tissues during MR-guided prostate cryoablation procedures.
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INTRODUCTION
Magnetic resonance (MR) imaging-guided cryoablation is an upcoming and promising 
minimally invasive treatment for localized prostate cancer (PCa)1-3. One of the main challenges 
in prostate cryotherapy is to achieve radical cancer ablation without inducing freeze injury 
to nearby vital structures4. As up to 70-80% of prostate cancers is located in the peripheral 
zone5, particularly the rectal wall and neurovascular bundles are at risk. In order to avoid 
complications, sub-zero temperatures should be avoided in the vicinity of these structures.
 Currently, temperature monitoring in tissues surrounding the ablation zone is performed 
using invasive thermocouple probes6-8. This approach may be time consuming, poses risks of 
puncture complications and only yields temperature measurements at discrete locations. A 
non-invasive imaging-based method would therefore be desirable.
 MR image-guidance of cryoablation enables monitoring of the ablation zone in three 
dimensions with excellent depiction of the ice-tissue boundary9,10. However, an important 
limitation of conventional imaging sequences is the inability to visualize the thermal gradient 
in tissues surrounding the ice-ball. Previously, several studies on the MR monitoring of 
cryoablation have noted a thin rim of increased signal around the ice-ball in fast T1-weighted 
(T1w) gradient echo (GRE) images, presumably representing the temperature gradient in 
adjacent cooled but non-frozen tissue11-13. Potentially, this image contrast could allow insight 
into the temperatures induced proximal to the ablation zone during MR-guided cryoablation 
procedures. However, to our knowledge, this signal deviation has never been experimentally 
investigated nor explored in vivo in patients.
 This study aims to correlate T1-weighted (T1w) MR image contrast around a cryoablation 
ice-ball with temperature in a phantom study and to compare this to its in vivo appearance 
during MR-guided focal cryoablation of prostate cancer (PCa).
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METHODS
THEORY
The effects of temperature on MR signal have previously been explored for several applications, 
including the monitoring of thermotherapy. Gultekin et al. reported a comprehensive overview 
of the temperature dependency of several MR properties and their combined effects on the 
magnitude of the MR signal14. Firstly, MR signal is proportional to the nuclear magnetization 
(M0), which has a negative temperature dependency (i.e. M0 will increase when absolute 
temperature drops). Secondly, MR signal is dependent on the relaxation times (T1, T2), 
which may differ at different temperatures, for different substances measured and depend 
on magnetic field strength15. In the temperature range above the freezing point, T1 exhibits 
a rather strong temperature dependency, showing a linear increase with temperature of 
approximately 1.0-2.0% per °C16-19. In addition, temperature dependency of T1 increases with 
field strength20. T2 on the other hand appears to be relatively temperature insensitive in the 
same temperature range17,18,21,22. Finally, experimental parameters such as echo time (TE) 
and repetition time (TR) determine the sensitivity of an MR sequence for the temperature 
dependent relaxation effects.
 In this study, a gel phantom and in vivo prostate tissue are imaged during cryoablation using 
a fast T1w GRE sequence at 1.5T. Above the freezing point, we anticipate that as tissue cools, 
equilibrium magnetization (M0) will increase as given from the Boltzmann distribution14. In 
addition, due to its linear temperature dependence, T1 is expected to shorten with decreasing 
temperature. Down to 0°C, this has also been experimentally demonstrated by Fung et al.20.
 As a result of these effects, in a GRE sequence14
 S (T) = M0(T) sin θ e-TE/T2*(T) (1 - e-TR/T1(T))(1 - e-TR/T1(T) cos θ)-1 (1)
a decrease in temperature (T) would give rise to an increase in received MR signal (S), with its 
magnitude modulated by the measurement parameters TE, TR and flip angle θ. Therefore, in a 
T1w GRE sequence, cooled tissue would be expected to exhibit increased signal as compared 
to uncooled tissue. Due to the exponential terms in Eq.1, this signal increase may be non-
linear. For freezing temperatures, MR signal is expected to be rapidly lost owing to extreme 
T2 shortening as free water is taken up into ice crystals23,24.
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PHANTOM STUDY
Three identical gel phantoms (23 x 14 x 6 cm) were prepared consisting of demineralized water 
and 3% carrageenan as a gelling agent. Following the method proposed by Kato et al., different 
concentrations of GdCl3 as T1 modifier and agarose as T2 modifier were added to obtain MR 
relaxation properties equivalent to prostate tissue at 1.5T (T1: 1317 ms; T2: 88 ms25) as well as 
NaCl to obtain tissue equivalent dielectric properties26,27. Prior to the experiments, phantoms 
were kept overnight in a stove set at 37°C in order to bring the gel to body temperature.
 Each phantom was positioned in a 1.5T MRI system (Magnetom Avanto, Siemens, Erlangen, 
Germany) with a body phased-array coil placed over the phantom for imaging. Using a perspex 
frame, an MR-compatible cryoneedle (IceRod, Galil Medical, Yokneam, Israel) was inserted 
into the phantom. Using plastic coaxial needles (Invivo, Schwerin, Germany), two fiberoptic 
temperature sensors (Neoptix, Québec, Canada) were inserted parallel to the cryoneedle at 
a lateral distance of 0.5 and 1.0 cm (Figure 1a). A third temperature sensor was placed on 
the contralateral side of the phantom for reference. Temperature readings throughout the 
experiment were recorded at 1 second intervals. Baseline T1 measurement was performed 
using four consecutive multi-slice spoiled GRE sequences with varying flip angles (TR = 3.85 ms, 
TE = 1.42 ms, FA = 2/5/10/20°, slice thickness = 3.6 mm, FOV = 260 mm, matrix size 160x160, 
averages = 6, acq. time = 43 s). Using the MRI SeedNet system (Galil Medical, Yokneam, Israel), 
freezing was applied until the ice-ball was maximal in size. Continuous MR monitoring of ice-
ball progression was performed using a coronal 3D T1w volume interpolated GRE sequence 
(TR = 4.81 ms, TE = 1.96 ms, FA = 6°, partition thickness = 2.5 mm, FOV = 250 mm, matrix 
size 192x192, averages = 1, phase oversampling = 0%, slice partial fourier = 6/8, PAT mode = 
GRAPPA, acc. factor PE = 2, no. of partitions = 26, pixel bandwidth = 389 Hz/pixel, acq. time 
= 11 s). At the end of the experiment, T1 measurement was repeated.
 After the experiments, MR images and temperature readings were analyzed using MATLAB 
R2011a (Mathworks, Natick, United States). In order to obtain signal intensity (SI) values 
representative for the sensor locations, its positions were mirrored across the center line of 
the cryoneedle (Figure 1b). For the mirror positions, SI over the experiment was extracted, 
normalized to its baseline value before cooling and related to measured temperatures.
For quantitative analysis, in the last image of each experiment, a linear region of interest (ROI) 
extending from 1 cm into the surrounding gel onto the center of the ice-ball was selected. 
SI along this line was normalized to its first three values and plotted against position. Full 
width at half maximum (FWHM) was used to determine the width of the hyperintense rim 
surrounding the ice-ball.
 Finally, T1 maps at baseline and end of ablation were generated using the variable flip angle 
(VFA) method28. For each experiment, mean T1 value at baseline was determined for a 5 x 5 
voxel ROI selected centrally in the phantom. Similarly, mean T1 value around the ice-ball at 
the end of ablation was determined for 10 voxels directly adjacent to the frozen area.
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CLINICAL PROCEDURES
The same T1w sequence was used during MR-guided focal cryoablation in 10 patients at our 
institution with biopsy-proven local recurrence after radiotherapy (n=9) or newly diagnosed 
prostate cancer (n=1) located in the peripheral zone (n=9) or transition zone (n=1). In all 
patients, informed consent was obtained. Procedures were performed on the same 1.5T 
MRI system and used the same imaging setup as in the phantom experiment. Patients were 
treated under general anesthesia. After insertion of a urethral warming catheter, patients 
were positioned in the lithotomy position. Axial and sagittal T2-weighted turbo spin echo (TSE) 
imaging was performed to relocalize the tumor. Cryoneedles were inserted transperineally 
into the target region under balanced steady state free precession (bSSFP) real-time MR image 
guidance. After confirming correct needle placement, a rectal warming balloon was inserted. 
During freezing, both warmers were flushed with warm (43°C) saline. Two cycles of 10 min. 
freezing and 3 min. thawing were applied. Ice-ball growth was continuously monitored in axial 
orientation using the 3D T1w volume interpolated GRE sequence (TR = 4.81 ms, TE = 1.96 
ms, FA = 6°, partition thickness = 2.5 mm, FOV = 250 mm, matrix size 192x192, averages = 2, 
phase oversampling = 88%, slice partial fourier = 6/8, PAT mode = GRAPPA, acc. factor PE = 
2, no. of partitions = 26, pixel bandwidth = 389 Hz/pixel, acq. time = 50 s). Further procedure 
details have been described previously2.
 After the procedures, MR images were analyzed quantitatively. In two patients, image 
quality was insufficient for quantitative analysis due to excessive noise. In each of the 
remaining eight patients, a similar linear ROI as in the phantom was selected in the last 
image of the procedure. Care was taken not to select the line ROIs in close proximity to the 
edge of the prostate or near the rectum or urethra. SI along the line ROIs was normalized 
to its first three values and compared to the phantom data by calculating the maximum and 
root mean square difference (RMSD) between the curves of both settings. FWHM was used 
to determine the width of the hyperintense rim surrounding the ice-ball.
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RESULTS
PHANTOM RESULTS
Baseline temperature of the phantom was 39.9±1.8°C. No substantial deviation (<1°C) from 
this baseline was observed at the contralateral side of the phantom during all experiments. 
Baseline T1 of the phantom was 1372±89ms.
 In the phantom, the ice-ball appeared in the fast T1w GRE images as a sharply delineated 
signal void, directly surrounded by a bright hyperintense rim. On correlation of MR images 
with the sensor readings, the rim coincided with temperature recordings in the gel near but 
above the freezing point (Figure 1c-e). Also when normalized SI is plotted against temperature, 
a pronounced signal increase can be observed in the cooled but non-freezing temperature 
range (<20°C) (Figure 2). When temperature entered the freezing range, normalized SI decayed 
rapidly with no measurable signal remaining at -5°C. Normalized SI was maximum at 8.4±2.4°C, 
showing a 35.6-43.0% (mean 40.5%) increase with respect to baseline before cooling. Width 
of the hyperintense rim was 2.2±0.2 mm. T1 directly adjacent to the ice-ball at the end of 
ablation was 631±72ms, showing a 54% shortening with respect to baseline (Figure 1f).
IN VIVO FINDINGS
In all clinical procedures, fast T1w GRE imaging allowed the continuous monitoring of ice-
ball progression. In the in vivo MR images, in all patients, the cryoablation ice-ball appeared 
similarly as in the phantom study, i.e. as a signal void surrounded by a hyperintense rim (Figure 
3). In vivo, normalized SI increases with respect to non-treated prostate ranged 28.4-55.6% 
(mean 36.8%).
 On quantitative analysis, normalized SI changes along the linear ROI at the end of ablation 
were similar between the phantom and in vivo data (RMSD 0.06, maximum difference 0.16) 
(Figure 4). In vivo, width of the hyperintense rim around the ice-ball was 1.6±0.6 mm.
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DISCUSSION
Similar studies on the MR monitoring of cryotherapy have mainly focused on measuring 
temperatures inside the ice-ball using ultrashort TE (UTE) sequences29-32. In contrast, this 
work focused on the monitoring of tissue external to and surrounding the cryoablation zone. 
Research exploring the use of novel MR strategies to visualize the temperatures induced 
in tissues around the frozen area is limited. Rothgang et al. have investigated the use of 
proton resonance frequency shift (PRFS) thermometry proximal to the cryoablation zone, 
however, high sensitivity of this technique to ice-ball induced susceptibility artifacts was 
found to considerably influence accuracy of the temperature maps and correction algorithms 
need further validation33,34. Alternatively, this study investigated T1w image contrast around 
the ice-ball, correlated it with temperature and explored its in vivo appearance in patients.
 In our phantom study (n=3), we found the hyperintense rim around the ice-ball in fast 
T1w GRE images to correspond to cooled but non-freezing temperatures (<20°C) proximal 
to the frozen zone. The signal increase at low temperatures can be mainly attributed to T1 
shortening. Normalized SI was maximum at 8.4±2.4°C. Theoretically, normalized SI would be 
expected to reach a maximum around 0°C, directly before the freezing-related signal loss35. 
This was also found experimentally by two studies that have used UTE imaging to investigate 
the temperature dependency of MR signal in the cryogenic range29,30. The incongruence 
with our findings is probably due to the use of a short TE (~2 ms) in our study compared to 
ultrashort TEs (~200 µs) applied in the latter experiments. At the ice-tissue transition, the 
susceptibility difference between the frozen and unfrozen tissue states may result in a local 
T2* decrease. Although 2ms was the shortest TE that could be set on the clinical MR system 
used in this study, this could have reduced the signal measured with our imaging sequence 
close to the ice-ball boundary.
 In vivo, normalized SI increases were in a comparable range with those in the phantom 
study, with the mean value appearing slightly lower in the patient setting (40.5 vs. 36.8%). A 
noted difference between findings in both settings was the smaller width of the hyperintense 
rim in vivo than in the phantom (~1.6 vs. 2.2 mm). This suggests that in the in vivo prostate 
the cooled non-freezing temperatures induced around the ice-ball are restricted to a smaller 
area as compared to the phantom, indicating the presence of a steeper spatial temperature 
gradient. Tissue perfusion, acting as a cold sink, or cellular boundaries affecting the extension 
of ice crystal formation could explain this observation.
 The contrast observed around the cryoablation ice-ball in fast T1w GRE imaging may hold 
potential for clinical use. The visualization of cooled non-freezing temperatures allows insight 
into the temperature distribution in the surrounding tissues. Particularly since there may 
be a considerable time gap between MR image acquisition, subsequent assessment of ice 
progression and cryoprobe modulation, this could be an important capability. In addition, 
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several studies on non-freezing cold injury have demonstrated free radical formation to 
occur at temperatures near but above the freezing point36,37. Potentially, monitoring of the 
hyperintense rim may then be useful in order to maintain a safe margin from at-risk structures. 
Nevertheless, our in vivo study was only explorative and a potential clinical use of our findings 
will need to be validated by including procedure-related complications and follow-up imaging 
or histopathology following cryotherapy.
 Some limitations of this study need to be acknowledged. In several animal studies 
on cryotherapy, temperature measurements have been obtained in vivo by means of 
thermocouples or fiberoptic probes29,32,38. In our patient group, no reference temperature 
measurements could be obtained in vivo. To the best of our knowledge, no MR-compatible 
temperature probes that are approved for in-patient use were commercially available at 
the time this study was conducted. To be able to compare results between the phantom 
and patient setting, care was taken to prepare the gel phantom with tissue-equivalent MR 
relaxation and thermal properties and to use the same imaging parameters in the phantom 
study as in vivo.
 In the phantom study, we chose to mirror the sensor positions across the cryoneedle in 
order to obtain representative SI values. In other studies, ROIs were chosen directly adjacent 
to or in an area around and including the temperature probes11,29. Due to the thermal gradient 
present in the tissue, any position offset may result in considerable error matching measured 
temperatures to SI. By mirroring the sensor positions, we tried to minimize any error in the 
correlation between normalized SI and temperature, assuming symmetric growth of the ice-
ball in the homogeneous gel phantom.
 In conclusion, this study has shown the hyperintense rim surrounding the ice-ball in fast 
T1w GRE images to correspond to cooled but non-freezing temperatures (<20°C) induced 
proximal to the frozen zone. We observed the same image contrast both in a phantom study 
as well as in vivo in the human prostate during cryotherapy. Potentially, monitoring of this 
rim could be useful in order to maintain a safe margin from adjacent at-risk tissues during 
MR-guided prostate cryoablation procedures.
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FIGURES
Fig 1 a) Setup for the phantom study showing the cryoneedle and temperature sensor positions at lateral 
distances of 0.5 (I) and 1.0 cm (II); b-e) Fast T1w GRE images at different time points during one of the phantom 
experiments with sensor locations (+) and mirrored positions (*) overlaid and corresponding temperature 
recordings indicated. f) Calculated T1 map (s) at the end of ablation reveals shortening of T1 directly adjacent 
to the ice-ball. Some distortion in the T1 map can be seen below the ice-ball arising from the artifact of the 
cryoprobe shaft.
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Fig 2 Normalized SI correlated with measured temperature for both sensor positions (I,II) 
in the three phantom experiments (A,B,C).
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Fig 2. Normalized SI correlated with measured temperature for both sensor positions (I,II) in the three phantom 
experiments (A,B,C). 
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Fig 3 a) Axial T2-weighted TSE image and corresponding b) axial dynamic contrast enhanced (DCE) image of 
diagnostic prostate MR examination in one of our patients prior to cryoablation, showing a cancer suspicious 
region in the right peripheral zone (outline). c) Axial T2w TSE image during the procedure shows two cryoneedles 
(arrows) positioned near the target area. d) Axial fast T1w GRE image acquired during cryoablation. The growing 
ice-ball (IB) is readily visible as a signal void directly surrounded by a bright hyperintense rim (arrowheads).
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Fig 3. a) Axial T2-weighted TSE image and corresponding b) axial dynamic contrast enh nced (DCE) image of 
diagnostic prostate MR examination in one of our patients prior to cryoablation, showing a cancer suspicious 
region in the right peripheral zone (outline). c) Axial T2w TSE image during the procedure shows two 
cryoneedles (arrows) positioned near the target area. d) Axial fast T1w GRE image acquired during 
cryoablation. The growing ice-ball (IB) is readily visible as a signal void directly surrounded by a bright 
hyperintense rim (arrowheads). 
 
         
  
Fig 4 a) Normalized SI along the linear ROI at the end of the ablation for the phantom experiments (blue) 
and patient group (red) with corresponding standard errors. b-c) Fast T1w GRE images at the end of one of the 
phantom experiments (b) and clinical procedures (c) shows the ROI selection.
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Fig 4. a) Normalized SI along the linear ROI at the end of the ablation for the phantom xperiments (blue) and 
patient group (red) with corresponding standard errors. b-c) Fast T1w GRE images at the end of one of the 
phantom experiments (b) and clinical procedures (c) shows the ROI selection.  
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FEASIBILITY AND ACCURACY 
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ABSTRACT
PURPOSE
To assess the feasibility and accuracy of 3D ultrashort echo time (UTE) MR thermometry of 
frozen tissue during cryoablation on a clinical 3T MR system.
MATERIALS AND METHODS
Ex vivo porcine muscle specimens (n=4) were imaged during two cycles of 10:3 minutes 
freeze-thaw on a 3T clinical MR scanner. Continuous MR monitoring was performed using a 
3D radial ramp-sampled UTE sequence with a shortest TE of 70 µs. Fiber optic sensors were 
used for temperature reference. Data of three experiments were used as reference sets. Signal 
intensity values were normalized to baseline before cooling and related to temperature. Data 
for subzero temperatures were fit to a mono-exponential function. In the separate validation 
set, the obtained fit was used to generate 3D MR temperature maps of frozen tissue at 
each imaging time point. Statistical analysis was performed to assess accuracy of the MR 
temperature maps.
RESULTS
With 3D UTE imaging MR signal was measured from frozen tissue down to temperatures as 
low as -40°C. Temperatures predicted from the MR temperature maps strongly correlated 
with sensor recorded values (r=0.977, p<0.001). Bland-Altman analysis demonstrated a mean 
difference between MR-estimated temperatures and sensor readings of –1.2±2.7°C with upper 
and lower limits of agreement of +4.1 and –6.5°C respectively.
CONCLUSION
3D MR thermometry of frozen tissue using UTE signal intensity was feasible during cryoablation 
on a clinical 3T MR system. Down to temperatures as low as -40°C, accuracy of the MR 
temperature maps was within clinically acceptable limits.
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INTRODUCTION
Magnetic resonance (MR) imaging-guided cryoablation is a promising minimally invasive 
image-guided therapy with applications in musculoskeletal, liver, kidney and prostate 
cancer1-5. MR imaging of cryoablation offers high soft tissue contrast as well as real-time 
three-dimensional (3D) monitoring of the freezing zone with excellent depiction of the ice-
tissue boundary.
 An important limitation of MR-guidance of cryoablation however is the inability to visualize 
the thermal variations present within the frozen tissue6. As effective treatment relies on 
achieving a sufficiently cold end temperature throughout the target lesion7,8, temperature 
feedback during these procedures is crucial. Invasive temperature probes only yield 
measurements at discrete locations and pose issues with MR-compatibility. An effective non-
invasive spatially resolved approach is warranted.
 A cryoablation ice ball presents as a sharply delineated signal void on conventional MR 
pulse sequences6,9. The intramolecular dipole-dipole interaction that leads to T2 relaxation is 
strongly dependent on the rotation correlation time of water. The rotation correlation time of 
water increases by orders of magnitude in the liquid to solid phase transition, thereby leading 
to strongly decreased T2 relaxation in frozen tissue10. More recently however, several studies 
have been able to acquire measurable MR signal from within frozen tissue using ultrashort 
echo time (UTE) imaging11-13. Wansapura et al. investigated the potential of MR thermometry 
of frozen tissue using UTE signal intensity and R2* and demonstrated the generation of 2D MR-
based temperature isotherms at the end of freezing in an in vivo canine prostate cryoablation 
experiment12. Furthermore, in another study the temperature dependency of these MR 
parameters was found to be consistent between different tissue types, offering potential for 
tissue-independent MR-thermometry13. As an important next step, the feasibility and accuracy 
to dynamically track temperatures across frozen tissue in 3D over the course of cryoablation 
remains to be established. When applied clinically, such capability could provide insight on 
the area that is effectively treated during MR-guided cryoablation procedures.
 Therefore we assessed the feasibility and accuracy of 3D UTE MR thermometry of frozen 
tissue during cryoablation on a clinical 3T MR system.
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MATERIALS AND METHODS
T2* AND T1 MEASUREMENT
Prior to the cryoablation experiments, T2* and T1 relaxation times of frozen tissue were 
assessed in order to optimize imaging parameters. An MR-compatible cryoneedle (IceRod, 
Galil Medical, Yokneam, Israel) was inserted into an ex vivo porcine muscle specimen (~5x5x10 
cm) at room temperature (~21°C) on a 3T clinical MR system (MAGNETOM Trio, Siemens, 
Erlangen, Germany). A body phased-array coil was used for imaging. Using an Argon/
Helium-based cryoablation system (MRI Seednet, Galil Medical, Yokneam, Israel), freezing 
was applied for 10 minutes. We used an RF-spoiled 3D UTE sequence with a 60 μs long non-
selective hard RF-pulse followed by a centre-out ramp-sampled radial read-out to achieve 
a shortest TE of 70 μs. The 3D UTE sequence was developed and provided as a work-in-
progress (WIP) package by Siemens AG (Erlangen, Germany). Eight subsequent image sets 
were obtained in two series: four sets at different echo times (TR=6.3 ms, TE=0.07/0.2/0.5/1.5 
ms, flip angle=15°, acquisition time=2:05 min) and subsequently four sets with different flip 
angles (TR=3.7 ms, TE=0.07 ms, flip angle=5/10/15/25°, acquisition time=1:14 min). Further 
imaging parameters included number of radial projections=20000, FOV=260 mm and matrix 
size=160x160x160. During acquisition of the image sets, temperatures within the frozen zone 
were kept approximately stable (largest temperature variation as measured by sensors <6°C) 
by continuous freezing at low intensity.
 After the measurements, in both data sets a single axial and coronal reformatted slice were 
selected centrally in the frozen zone. In each set, in the image with the lowest signal-to-noise 
(SNR) ratio, i.e. the latest echo for the T2*-set and flip angle=5° for the T1-set, the mean noise 
level was determined in a region-of-interest at the center of the ice ball where no measurable 
MR signal remained. T2* values were then calculated on a voxel-by-voxel basis by a linear 
least square fit of the natural logarithm of the signal from the echoes, where signal values 
higher than the mean noise level plus three standard deviations were considered reliable 
data points and included in the fit. T1 relaxation times were calculated from the signal at 
each flip angle following the variable flip angle method14, again including signal values higher 
than the mean noise level plus three standard deviations in the fit and using a modified Ernst 
equation to correct for in-pulse transverse relaxation effects resulting from short T2s in the 
frozen tissue15,16.
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CRYOABLATION EXPERIMENTS
Following relaxation parameter characterization, four identical cryoablation experiments were 
performed. Ex vivo porcine muscle specimens of similar size were prepared using the same setup 
and in the same 3T MR system as described above. Using coaxial needles with plastic sheaths, 
three fiber optic temperature sensors (T1, Neoptix, Quebec, Canada) were placed parallel to the 
cryoneedle at lateral distances of 5, 10 and 15 mm (Figure 1A). T1-weighted volume interpolated 
(VIBE) gradient echo imaging (TR=6.0 ms, TE=3.0 ms, flip angle=5°, partition thickness=2.5 mm, 
no. of partitions=32, FOV=200 mm, matrix size=192x192, averages=2 and acquisition time=1:00 
min.) was performed in coronal orientation at the start of each experiment to map the exact 
locations of the temperature sensors (Figure 1B). Using the same cryoablation system, two 
cycles of 10:3 min. freeze-thaw were applied. During all experiments, temperature readings from 
the sensors were recorded at 1 second intervals. Continuous MR monitoring of ice progression 
was performed using the same 3D UTE sequence as described above, with following imaging 
parameters: TR=3.7 ms, TE=0.07 ms, flip angle=15°, number of radial projections=20000, 
FOV=260 mm, matrix size=160x160x160 and acquisition time=1:14 min.
NOISE CORRECTION
After completion of the cryoablation experiments, the magnitude MR signal intensity (SI) 
values were corrected for noise bias. Inherently, magnitude image data is systematically 
biased due to the noise. In particular at low signal-to-noise levels, the existence of a noise 
floor may cause considerable error on fitting of the data, but a correction method has been 
described17. Prior to each cryoablation experiment, two subsequent image sets were obtained 
at room temperature using the same measurement parameters as above. These sets were 
subtracted and for a region-of-interest of 10x20 voxels within the tissue specimen, the mean 
absolute difference (M) was determined. The true noise σn was then calculated using M/
(π/2)1/2. Signal intensity values of the experiments were then squared and the true noise 
power (σn
2) subtracted from them. The noise corrected SI values were then given by the 
square root of the subtracted values.
SIGNAL INTENSITY MEASUREMENTS
Data of three separate cryoablation experiments were used as reference sets. For each 
experiment, per location of a temperature sensor we recorded noise corrected SI values 
for three different voxels at the same radial distance from the cryoneedle in order to obtain 
representative signal values for the sensor positions. SI data were normalized to their baseline 
value before cooling and related to temperature. All data points for subzero temperatures 
were fitted to a mono-exponential function.
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MR TEMPERATURE MAPS
In a separate validation set, the previously obtained curve fit was used to convert normalized 
signal values to temperature values and generate MR temperature maps of the frozen tissue. 
In the temperature maps, per location of a temperature sensor we selected three voxels at 
the same radial distance from the cryoneedle. For these voxels, temperatures predicted from 
the MR temperature maps were assessed over the course of the cryoablation experiment 
and compared with sensor recorded values at matched time points.
STATISTICAL ANALYSIS
Data are reported as mean ± standard deviation (SD). Accuracy of the MR temperature 
maps was analyzed as follows. Pearson’s correlation coefficient (r) was determined between 
temperatures derived from the MR temperature maps and the sensor recorded values as a 
measure for the strength of the linear relationship between the two measures. The coefficient 
of determination (R2) of the data points, consisting of the MR-estimated temperatures and 
sensor readings, to the line of identity was calculated to provide an indication of how well 
the MR-estimated temperatures approximated the sensor measured values. Additionally, we 
assessed the level of agreement between the two measures using the Bland-Altman approach, 
producing a scatter plot of the difference between the two measures against their mean18. 
Mean difference as well as upper and lower limits of agreement, i.e. the symmetric range 
encompassing 95% of the data, were calculated and displayed in the same graph. Statistical 
analysis was performed using SPSS (Version 20.0).
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RESULTS
T2* AND T1
Calculated T2* and T1 maps of the frozen tissue are shown in Figure 2A-B. Both parameters 
showed strongly reduced relaxation times within the frozen tissue as compared to non-
frozen surrounding tissue. T2* abruptly decreased from 12±1 ms in non-frozen tissue to 
approximately 2-3 ms in the periphery of the frozen zone (Figure 2C). As temperature is further 
decreased, T2* decreased more gradually in an inward radial pattern down to approximately 
0.5-1 ms close to center of the ice ball. T1 rapidly decreased from 567±117 ms in surrounding 
tissue to approximately 150-200 ms just inside the frozen zone (Figure 2C). Closer to the ice 
ball center, T1 decreased further down to around 50-100 ms. Some variation in T1 can be 
seen across the frozen tissue but in contrast to T2*, a distinct pattern with temperature is 
less clearly recognizable. In the exact center of the ice ball, relaxation values could not be 
reliably estimated as too little signal remained at the low temperatures directly adjacent to 
the cryoneedle.
SIGNAL INTENSITY
All data presented from this point is based on images obtained with the shortest TE of 
70µs. Representative 3D UTE images acquired at different time points and during different 
phases of one of the cryoablation experiments are shown in Figure 3. UTE MR signal changes 
corresponded well with temperature variations over time (Figure 4), demonstrating the 
feasibility to dynamically track these changes across frozen tissue over the course of two 
cryoablation cycles.
 The normalized corrected SI is shown as a function of temperature for the three reference 
sets (Figure 5). Initially, as the tissue cools towards the freezing point, there is an increase 
in signal which can be attributed to T1 shortening and an increase in net magnetization19–23. 
For subzero conditions, UTE MR signal decreased mono-exponentially with temperature (T), 
with the signal decay fitted by normalized SI = 1.41*e0.06T (R2=0.89).
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MR TEMPERATURE MAPS
Using the fit of the reference sets as a calibration curve, we could obtain MR temperature 
maps of the frozen tissue in 3D at each imaging time point in the validation set (Figure 6). Over 
the course of two cryoablation cycles, temperatures predicted from the MR temperatures 
maps were seen to closely follow the sensor recorded values (Figure 7).
 When MR-estimated temperatures were plotted against sensor recorded values, there was 
a strong positive correlation between the two measures (r=0.977, p<0.001). Linear regression 
analysis yielded the following relationship: T
MR-estimated 
= 1.01Tsensor - 1.13. R
2 of the data to the 
line of identity was 0.94 (Figure 8A). Bland-Altman analysis demonstrated a mean difference 
between MR-estimated temperatures and sensor readings of –1.2±2.7°C, with upper and 
lower limits of agreement of +4.1 and –6.5°C respectively (Figure 8B). There was little evidence 
for a proportional error, with the individual points appearing randomly scattered around the 
mean difference.
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DISCUSSION
On our way towards subzero temperature measurements during clinical cryoablation 
procedures, this work explored the feasibility and accuracy of 3D UTE MR thermometry during 
cryoablation on a clinical MR system at 3T. We demonstrated 3D UTE imaging to achieve 
measurable MR signal from frozen tissue down to temperatures as low as -40°C within a 
clinically realistic time-frame (~1min) and with sufficient spatial resolution (1.63mm isotropic). 
Using a calibration curve, we could derive MR temperature maps of the frozen tissue, which 
showed good agreement with sensor readings over the course of two cryoablation cycles.
 When tissue freezes, free or bulk water transitions into ice crystals and does not contribute 
to the MR signal. Nuclear magnetic resonance (NMR) experiments have shown though that a 
fraction of approximately 10-20% of the tissue water remains mobile10,24. This ‘non-freezable’ 
water is bound to the hydration layer of macromolecules and is believed to be the source 
of the MR signal observed from frozen tissue in UTE imaging. Its relation with temperature 
has been previously studied by several investigators12,13,25. A study by Daniel et al. obtained 
preliminary data indicating that the magnitude of the MR signal observed in short TE gradient 
echo imaging of frozen tissue decreased gradually with temperature down to approximately 
-30°C25. Another study investigated the relation between MR signal intensity and temperature 
in the in vivo prostate in five canine experiments using eddy-current compensated half RF-
pulse UTE imaging and found an exponential relation between UTE MR signal and temperature 
for temperatures <0°C12. In this work, we also demonstrated an exponential relation between 
UTE MR signal and temperature below the freezing point. The exact relations between our 
studies are not identical though and differences can be seen in the tissues that were imaged 
(ex vivo porcine muscle vs. in vivo canine prostate) and imaging parameters that were used. 
With T2* values inside the frozen zone in the order of few milliseconds, mainly the used TE 
directly influences the MR signal that can be measured from frozen tissue. In this work a 
shortest TE of 70 µs was used as compared to 208 µs in the previously cited work, which may 
have enabled us to still detect MR signal towards lower temperatures. Additionally, imaging in 
this work was performed on a higher magnetic field (3T as compared to 0.5T), which increased 
our sensitivity to low signal levels inside the frozen tissue as well. A further difference between 
our measurement protocols exists in the influence of T1-weighting. This is mostly reflected in 
the part of the signal curve above the freezing point, where with decreasing temperature we 
observed a higher relative signal peak prior to the freezing-related signal loss. Lastly, signal 
normalization between our studies was performed to different temperatures, i.e. relative 
to tissue at room temperature in this work as compared to in vivo prostate tissue in the 
previously mentioned work, which altered the relative signal curves as well.
 The origin of contrast for MR thermometry in this work was UTE signal intensity. This 
approach utilizes the signal of the shortest echo time and has the advantage of a high signal-
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to-noise. Additionally, since each measured image set could be used to provide temperature 
information, it allowed dynamic 3D thermometry within a relatively short measurement 
time. Next to signal intensity, other temperature-sensitive MR parameters may potentially be 
used for temperature mapping of frozen tissue. Changes in T1 relaxation with temperature 
have previously been demonstrated in ex vivo frozen tissue samples using pulsed NMR 
spectroscopy20,21,24,26. However, as the behavior of T1 with temperature below the freezing 
point was found to be non-monotonic, its use for MR thermometry of cryoablation appears 
limited. Also, in the T1-map obtained in this work no evident relation of T1 with temperature 
was observed. Although some variation in T1 is seen across the frozen tissue between different 
sides of the sample, this is most likely the result of B1 inhomogeneity and it is unlikely that 
this reflects a temperature-related effect. For T2*, a more clear relation with temperature 
was found, where T2* was seen to decrease with temperature from just below the freezing 
point at the periphery of the frozen zone towards lower values closer to the cryoneedle in 
an inward radial pattern. This observed pattern correlates well with findings of two other 
studies that previously explored the feasibility of T2*-based MR thermometry of frozen tissue 
and showed similar behavior of T2* with temperature in the subzero temperature range12,13. 
One potential advantage of the use of T2* for MR thermometry of frozen tissue would be its 
independence of measurement parameters and coil position, which needs to be accounted for 
in the signal intensity-based approach. Also, the method could be used without the need to 
acquire a baseline reference, which could make a T2*-based approach more robust to organ 
shift or patient motion. Nonetheless, an important drawback of T2*-based MR thermometry 
lies in the increased acquisition time that is required to obtain the image sets at different echo 
times needed to estimate the relaxation rate. This could render it less favorable within a clinical 
time frame, particularly when dynamic thermometry is desired. Also, SNR is decreased with 
the images obtained at later echoes, which could reduce accuracy of this method.
 We assessed the accuracy of MR temperature maps obtained through UTE signal intensity 
in conjunction with a calibration curve using Bland-Altman analysis. As for the interpretation 
of our findings, it should be noted that no statistical test can fully affirm what represents 
adequate agreement and this should be determined from a clinical perspective. In cryotherapy, 
an end temperature of -40°C is generally regarded to be required for effective tissue necrosis7,8. 
Although some experimental in vitro data suggest that with repetition of freeze-thaw cycles 
and high cooling rates this lethal temperature threshold may be raised, e.g. to around -20°C27, 
there is insufficient data to verify this result in vivo and cell destruction may be uncertain or 
incomplete8. Clinically, the reliable measurement of temperatures down to -40°C would thus 
be an important lower limit. In our view, the accuracy of the proposed method in this work 
(i.e. largest temperature error ~6°C) could already be useful in a clinical context, particularly 
since there is currently no other method available to non-invasively measure temperatures 
within frozen tissue. A relative signal level (e.g. of 18%) as compared to baseline before cooling 
may be identified as a threshold below which temperatures are below a certain value, e.g. 
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-40°C. This could be helpful information during cryoablation treatment to estimate the area 
that is effectively treated.
 Nevertheless, the present work is limited to a small number of normal muscle tissue 
specimens in the ex vivo setting. In this way, we could precisely place and locate the cryoprobe 
and temperature sensors in order to accurately match the temperature and image data. To 
apply this method clinically, it should be validated how ex vivo calibration curves translate to 
the in vivo setting. Furthermore, care should be taken that intraprocedural images are obtained 
with the same imaging parameters as the calibration curve, in order to eliminate dependence 
of the signal on the measurement parameters. Finally, it should be validated whether fast 3D 
UTE acquisitions (imaging times <2 min.) are able to achieve sufficient SNR to measure signal 
variations within in vivo frozen tissue as well, particularly for deeper lying organs which lie 
further away from the receive coil than the ex vivo samples in our experiments.
 Another limitation of this work that inherently affected our measurements is temperature 
averaging. Due to the presence of a spatial temperature gradient, a temperature difference 
exists between two ends of a voxel. Based on the cryoneedle specifications provided by 
the manufacturer, an estimation of the temperature gradient between the -20 and -40°C 
isotherm can be derived of ~3.6°C/mm along the short axis. Given a voxel size of 1.63 mm, 
this would correspond to an estimated intravoxel temperature difference in the order of 
~6°C. Complementary to the above, the absolute temperature values present within a given 
voxel will change dynamically over time during image acquisition as well, resulting in an 
additional averaging effect.  This is expected to be greatest for the sensor position closest to 
the cryoneedle where both freezing rate (Δ°C/min.) and spatial temperature gradient (°C/
mm) are highest. Despite this effect though, a temporal resolution of 1:14 min. seemed to 
provide adequate accuracy in tracking the temperature-induced MR signal changes, even for 
the faster variations occurring at the transition from the freeze to thawing phase.
 Finally, our results may also be relevant for cryoablation treatment models. Several 
groups have been exploring computerized models to prospectively predict the temperature 
distribution achieved during cryoablation for the purpose of individualized treatment 
planning28-30. Our 3D temperature data provides a means to validate these models by 
comparing numerically simulated temperature isotherms with those derived from the UTE 
MRI data. Such feedback may be valuable to optimize the accuracy of these models and may 
add to the development of effective planning tools for the clinic.
 In conclusion, we have demonstrated with this work the feasibility of 3D MR thermometry 
using UTE signal intensity to dynamically track temperatures across frozen tissue during 
cryoablation on a clinical MR system at 3T. Down to temperatures as low as -40°C, accuracy 
of the obtained MR temperature maps was within clinically acceptable limits.
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FIGURES
Fig 1 A) Schematic overview of the experimental setup shows the cryoneedle and parallel placement of three 
fiber optic temperature sensors at 5mm intervals; B) T1w VIBE image shows the same setup at the start of one of 
the cryoablation experiments, with different sensor positions indicated with colored asterisks (*)
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Fig 1. A) Schematic overview of the experimental setup shows the cryoneedle and parallel placement of three 
fiber optic temperature sensors at 5mm intervals; B) T1w VIBE image shows the same setup at the start of one 
of the cryoablation experiments, with different sensor positions indicated with colored asterisks (*). 
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Fig 2 A,B) Axial and coronal reformatted slices of the 3D UTE data sets centrally within the frozen zone (left 
columns), with corresponding calculated T2* and T1 maps (right columns). Markedly reduced relaxation times 
can be seen inside the frozen zone as compared to the surrounding unfrozen tissue. In the exact center of the 
freezing zone, relaxation values could not be estimated as no measurable MR signal remained. C) Distribution 
of T2* (left) and T1 values (right) plotted against position along a horizontal line from the edge of the specimen 
onto the most central point inside the frozen zone where relaxation parameters could still be estimated.
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Fig 3 A) Axial (top) and reformatted coronal (bottom) UTE images  (TE=70µs) at 0, 305, 613 and 1380 seconds 
into one of the cryoablation experiments, with locations of the temperature sensors indicated in the first image 
(*); B) T1-weighted VIBE image (TR/TE/FA=6.0/2.0ms/6°) acquired directly after the last UTE image is shown for 
comparison in full window setting, illustrating the necessity for ultrashort TEs to obtain measurable MR signal 
from inside the frozen zone.
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Fig 4 Normalized SI changes with standard error over time during one of the cryoablation experiments plotted 
for subzero temperatures. Colors indicate data corresponding to the different sensor positions. Recordings from 
the temperature sensors are displayed in the same graph (dashed lines). After freezing is started, temperature 
can be seen to rapidly drop below the freezing point for the sensors located at 5 and 10mm, with a faster rate 
occurring closer to the cryoneedle. At the same time, normalized SI is seen to rapidly decline, with the rate 
appearing to correlate with the temperature change. When freezing is ceased after the first ten minutes, the 
sensors registered a rapid temperature increase centrally in the frozen area. At corresponding positions in the 
tissue, normalized SI demonstrated a rapid signal recovery as well, again following the rate of the temperature 
change. Over the second freeze-thaw cycle the same pattern can be observed.
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Fig 5 Normalized noise corrected SI data of the three reference sets plotted as a function of temperature, 
with colors indicating data corresponding to the different sensor positions. For temperatures below the freezing 
point, UTE MR signal decreased mono-exponentially with temperature, with the obtained curve fit overlaid.
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Fig 5. Normalized noise corrected SI data of  thr e ref rence se s plotted as a function of tempe ature, with 
colors indicating data corresponding to the different sensor positions. For temperatures below the freezing 
point, UTE MR signal decreased mono-exponentially with temperature, with the obtained curve fit overlaid. 
  
Fig 6 Axial and reformatted coronal UTE images (A,B: top rows) at different time points in the validation set, 
with corresponding generated MR temperature maps (A,B: bottom rows) that were obtained through the curve 
fit of the reference sets. The temperature overlay is only valid for the frozen zone, as the calibration applies to 
subzero temperatures. In close proximity to the cryoneedle, some distortions can be seen due to the artifact 
arising from the needle shaft.
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Fig 7 Temperatures predicted from the MR temperature maps with standard error (dashed lines) plotted 
against sensor recorded values (solid lines) over time during cryoablation in the validation set, with colors 
corresponding to the different temperature sensor positions. MR-estimated temperatures closely approximated 
sensor recorded values over the course of two cryoablation cycles.
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Fig 7. Temperatures predicted from the MR temperature maps with standard error (dashed lines) plotted 
against sensor recorded values (solid lines) over time during cryoablation in the validation set, with colors 
corresponding to the different temperature sensor positions. MR-estimated temperatures closely 
approximated sensor recorded values over the course of two cryoablation cycles. 
 
  
Fig 8 A) Scatter plot of MR-estimated temperatures as a function of sensor measured temperatures at matched 
time points. R2 value of the data to the line of identity is shown in the top left corner; B) Bland-Altman plot of 
MR-estimated and sensor measured temperatures shows the mean difference (solid line) and upper and lower 
limits of agreement (dashed lines) between both measures.
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Fig 8. A) Scatter plot of MR-estimated temperatures as a function of sensor measured temperatures at 
matched tim  points. R2 value of the data to the line of identity is shown in the top left corner; B) Bland-
Altman plot of MR-estimated and sensor measured temperatures shows the mean difference (solid line) and 
upper and lower limits of agreement (dashed lines) between both measures.  
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ABSTRACT
PURPOSE
To evaluate feasibility, adverse events, quality of life (QoL) and local cancer control after focal 
salvage MRI-guided cryoablation in patients with local radio-recurrent prostate cancer (PCa).
MATERIALS AND METHODS
A retrospective, single-center study was performed in 41 patients with radio-recurrent PCa 
who underwent MRI-guided cryoablation since May 2011 and a follow-up of ≥12 months in 
December 2015. Feasibility and adverse events were reported with rates and description 
of adverse events. Surgical complications were classified according to the Clavien system. 
Validated questionnaires were used to observe functional outcomes and QoL before therapy 
and after 6 and 12 months. Cancer control was defined as no biochemical failure according 
to Phoenix-criteria and no other clinical, radiological or histopathological evidence for local 
or metastatic disease.
RESULTS
All procedures were technically feasible. The number of life-threatening adverse events 
(Clavien-grade 4) or complications needing intervention under general anesthesia (Clavien-
grade 3b) was low, with respectively n=1 (2.4%) for both Clavien-grades. After 12 months, the 
ICIQ-SF- (p=0.001) and IIEF-5 scores (p=0.024) became significantly worse, indicating increased 
symptoms of incontinence and decreased erectile function, without compromising for QoL. 
Five patients developed metastases within 6 months and probably had micrometastatic 
disease at the time of treatment. After 12 months, 23 patients (59%) was disease free.
CONCLUSION
Focal salvage MRI-guided cryoablation is feasible and shows a positive balance between 
adverse events, functional outcome, QoL and local cancer control. This treatment can be 
a reasonable alternative with low morbidity to salvage radical prostatectomy in properly 
selected patients, however longer follow-up is needed. 
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INTRODUCTION
Biochemical recurrent prostate cancer (PCa) after a form of radiotherapy occurs in 
approximately 26–52% of the patients1,2. At present, salvage radical prostatectomy (SRP) can 
be performed. This has a curative intent, but is technically challenging because of radiation-
induced fibrosis and shrinkage of the prostate gland, resulting in high rates of urinary 
incontinence and rectal injury (0-28% and 0-67%, respectively)3,4 which severely affects the 
quality of life (QoL). In addition, surgery is contraindicated in most patients because of their 
age and comorbidities. Androgen deprivation therapy (ADT) can be an alternative. However, 
the latter is unattractive because of its temporary effect, which can lead to an increased risk 
of cardiovascular mortality, skeletal fracture and a decreased QoL5,6.
 Minimally invasive treatments have emerged to serve as alternative salvage therapy, i.e. 
high intensity focused ultrasound, high-dose brachytherapy and cryoablation. In case of a 
local recurrence, these minimally invasive treatments can be applied locally7-13. Goal is to treat 
localized tumors only to obtain local cancer control, while sparing the rest of the prostate to 
minimize potential morbidity.
 Accurate image guidance is of utmost importance to enable focal treatment. In contrast to 
ultrasound imaging, magnetic resonance imaging (MRI) is able to accurate lesion targeting 
and treatment monitoring during cryoablation. Ice-ball growth can be monitored in real-time 
and in multiple planes, such that damage to adjacent critical structures as the rectal wall can 
be minimized14.
 Additionally, local recurrent disease after radiotherapy may be very suitable for focal 
treatment, because it is more often unifocal (72% vs. 17%) and has a smaller cancer volume 
(0.68 cm3 vs. 3.43 cm3) compared to primary PCa15,16. Furthermore, local recurrences are likely 
to occur at the same site as the index lesion before radiotherapy17,18.
 Because of aforementioned reasons, we hypothesized that focal salvage MRI-guided 
cryoablation might be a reasonable alternative to SRP, particularly in patients with significant 
chance on comorbidities but with a significant life expectancy.
 The purpose of this study was to evaluate the feasibility, adverse events, QoL and local 
cancer control in patients with locally recurrent PCa after radiotherapy using this novel 
treatment approach. 
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MATERIALS AND METHODS
STUDY DESIGN AND PATIENTS
Between May 2011 and December 2015, 53 consecutive patients underwent focal salvage 
MRI-guided cryoablation of the prostate after previous radiotherapy. Before treatment, all 
patients underwent multi-parametric (mp-)MRI to localize the recurrence. Furthermore, all 
were negative on macroscopic metastatic screening with abdominal and pelvic MRI.
 In December 2015, 41 patients had a follow-up of ≥12 months and were included in our 
study (Figure 1). No restrictions were placed on characteristics of pre-radiotherapy cancer, 
PSA levels, Gleason score and stage of recurrent disease. All patients gave written informed 
consent for being treated with MRI-guided focal cryoablation and using their anonymized 
data for publication. A small study describing the feasibility results of the first 10 patients 
was published before19.
PROCEDURES
Patients were admitted to the hospital on the night before (n=19) or a few hours before 
treatment (n=22). Antibiotic prophylaxis (Ciprofloxacine) was started for 14 days at admission 
and they were given a cleansing enema to remove faeces.
 All patients were treated in a closed-bore 1.5 (n=14) or 3-Tesla (T) (n=27) MR-system 
(Magnetom Avanto/Skyra; Siemens, Erlangen, Germany) under general anesthesia. 
Cryoablation was performed with a MRI-compatible cryoablation device (MRI SeedNet; 
Galil Medical, Yokneam, Israel). Multiple cryoneedles (IceSeed/IceRod; Galil Medical) were 
transperineally inserted in the tumor under MRI-guidance19. During freezing, the urethra 
and the rectal wall were protected with warming catheters. In every patient two freeze-thaw 
cycles were performed. After the procedure, the cryoneedles and the rectal warmer were 
removed and the urethral warmer was changed for a Foley-catheter. Patients were discharged 
the day after treatment. When spontaneous voiding was not possible, a Foley-catheter was 
inserted for another 7 days.
 Follow-up consisted of urological checkups at 1-3, 6 and 12 months for PSA-tests and 
adverse event reporting. At 3, 6 and 12 months a mp-MRI was performed to determine 
local cancer control. MRI-guided biopsies were performed when a tumor suspicious region 
was seen on the mp-MRI. Since August 2013, the mp-MRI at 12 months was followed by 
2-3 targeted MRI-guided biopsy samples of the edge/rim of the ablated region to confirm 
treatment success with histopathology. If biopsies were positive, patients could be retreated 
with MRI-guided cryoablation after multidisciplinary consensus with the urologist, radiation-
oncologist and interventional-radiologist. From January 2013, patients were asked to complete 
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validated questionnaires (IPSS, ICIQ-SF, IIEF-5 and FACT-P19-22) before therapy and after 6 and 
12 months.
 Primary outcomes of the study were feasibility, adverse events, functional outcome and 
QoL. Feasibility and adverse events were reported with rates and description of adverse 
events. Surgical complications were classified according to the modified Clavien system for 
reporting surgical complications 23. The IPSS (including the IPSS-QoL questionnaire) and ICIQ-SF 
were used to assess urinary function and to define the proportion of men who were leak-
free (<1x/day urinary leakage). High IPSS, IPSS-QoL and ICIQ-SF scores indicated poor urinary 
functioning. The IIEF-5 questionnaire was used to assess the potency, defined as being capable 
of having erectile function sufficient for penetration, as well as total IIEF-5 score. A low IIEF-5 
score indicated poor erectile function. QoL was assessed with FACT-P with summary measures 
of the FACT-Prostate score, FACT-General score and the Trial Outcome Index (TOI) score. High 
scores indicated a better QoL.
 Secondary outcome of the study was to determine cancer control, which was defined as 
no biochemical failure according to the Phoenix criteria (PSA nadir+2) and no other clinical, 
radiological or histopathological evidence for local recurrent or metastatic disease.
STATISTICAL ANALYSIS
Missing values for individual questions were imputed based on known clinical data as was 
reported to the urologist. Because of the retrospective design of our study, not every patient 
filled in questionnaires at every time point. Data of all patients who filled in the questionnaires 
of at least one time point (n=32) were used in generalized-least-squares analyses using 
unstructured covariance matrix for residuals to accommodate the repeated measurements. 
Outcomes were reported as point estimates with 95% CIs to demonstrate level of precision. 
P-values <0.05 were considered significant. All statistical analyses were performed with SPSS 
(version 22).
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RESULTS
In total, 41 men were included in our study. One patient died 5 months after MRI-guided 
cryoablation from an unrelated stomach perforation. Another patient was diagnosed with 
colon cancer 2 months after MRI-guided cryoablation and was therefore excluded from follow-
up analyses. Patient characteristics of all patients are summarized in Table 1.
Forty-four procedures were performed in 41 patients. Three patients (7.3%) were re-treated 
with focal salvage MRI-guided cryoablation because of local recurrent (n=2) or remnant (n=1) 
tumor after the first procedure.
FEASIBILITY AND ADVERSE EVENTS
Due to the inability of inserting the urethral warmer in the second patient, one procedure was 
cancelled and successfully repeated two months later. All other procedures were technically 
feasible and no per-procedural complications were reported. Procedure characteristics are 
summarized in Table 2.
 Thirty-eight patients (92.3%) were discharged the day after treatment. The very first patient 
was monitored for two nights and went home without complications. Two patients had to stay 
one more night because of acute urinary retention. They went home with a Foley-catheter 
for 7 days. Six months later one of them developed a urethral stricture, which was surgically 
treated (Clavien grade (CG)3b). Afterwards he needed clean-intermittent catheterization (CIC). 
One patient was hospitalized for 17 days because he suffered from a myocardial infarction the 
day after the cryoablation. This man had a medical history of cardiac disease and underwent 
cardiovascular interventions before. Although it is not clear that the myocardial infarction 
was related to the cryoablation procedure, it was defined as a CG4a complication.
 Seven other patients had acute urinary retention and six of them went home with a Foley-
catheter for 7 days (CG1). In the seventh patient placement of a Foley-catheter was not 
possible due to prostate swelling and a temporary suprapubic catheter was placed (CG3a). 
None of the patients experienced voiding problems after removal of the catheter.
 In the months after cryoablation patients reported urinary retention needing CIC once 
a day (n=2, CG1); urinary incontinence, needing several pads per day (n=2, CG1); stress/
urge incontinence (n=9, CG1); a perineal wound, which resolved after 2 weeks (n=1, CG1) 
and urinary tract infections needing antibiotics (n=4, CG2). After three months, one patient 
developed a rectovesical fistula which was conservatively treated by placing a suprapubic 
catheter (CG3a). Another patient developed a rectoprostatic fistula one month after 
treatment. By way of precaution a Foley-catheter was placed for a few weeks (CG1). This 
fistula resolved spontaneously within 3 months. All adverse events defined according to the 
Clavien classification are summarized in Table 3.
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FUNCTIONAL OUTCOME AND QUALITY OF LIFE
All scores are summarized in Table 4 and shown in Figure 2 and 3. Between baseline and 
12 months, ICIQ-SF scores increased significantly (p=0.001), indicating increased symptoms 
of incontinence. One year after treatment IIEF-5 scores decreased significantly (p=0.024), 
indicating decreased erectile function. No significant differences were seen in IPSS or IPSS-
QoL-scores, when comparing baseline scores with scores 12 months after treatment.
 At baseline, 91.3% (21/23) of the patients was leak-free this declined to 60.9% (14/23) 
after 12 months. Before treatment, ten patients reported to have erections sufficient for 
penetration, after 12 months 6/10 (60.0%) preserved their potency. Between baseline and 12 
months, no significant differences were seen in the QoL scores for total FACT-P, FACT-G and TOI.
CANCER CONTROL
The cancer control outcomes are summarized in Figure 4. Six months after MRI-guided 
cryoablation 32 patients (82.2%) were disease free. One patient developed biochemical 
recurrence, another patient was diagnosed with local disease based on suspicious findings 
on mp-MRI. Five patients were diagnosed with metastatic disease. These patients may have 
had micro-metastases at the time of their MRI-guided cryoablation, which were not detected 
during pre-treatment imaging.
 Between 6 and 12 months, another nine patients showed disease progression. Two of them 
were diagnosed with metastases, seven other patients were diagnosed with local disease. 
After multidisciplinary consensus with the urologist, radiation-oncologist and interventional-
radiologist, three of them were retreated with MRI-guided cryoablation. Consequently, 23 
patients (59.1%) were disease-free after 12 months.
 MRI-guided biopsy of the edge of the ablation zone was performed in fifteen patients after 
12 months. Although the mp-MRI showed no signs of disease, vital tumor cells were found in 
3/15 (20%) patients. In one patient only a few individual tumor cells were found. In the other 
two patients, maximal tumor lengths of respectively 1 and 4 mm were found.
LEARNING CURVE
Three patients were retreated with MRI-guided cryoablation. Retrospective analysis of  the 
intra-operative MR images showed that in 1 out of 3 patients the ice-ball did not cover the 
complete tumor. This happened in our first patient and may be attributed to our learning 
process of conservative treatment in the first few procedures to minimize potential morbidity. 
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DISCUSSION
We demonstrated that focal salvage MRI-guided cryoablation in patients with PCa recurrence 
after radiotherapy is feasible and appeared to show a positive balance between adverse 
events, functional outcome, QoL and cancer control in this patient group. The number of 
life-threatening adverse events or complications needing intervention under anesthesia was 
low (n=2, 4.9%). After 12 months, only the ICIQ-SF- and IIEF-5 scores became significantly 
worse, without compromising the QoL.
 A low complication and morbidity rate is also reported by other studies on focal salvage 
therapy7-13,24,25. This is in contrast to the results after SRP. A systematic review averaging the 
results of 24 studies, reported an incontinence rate of 50%, bladder neck stricture in 26%, 
rectal injury in 5% and rectal fistula in 2.4% of the patients after SRP26. Although our reported 
complication rate is lower, our study is not directly comparable to these previous studies. 
Reasons for this are different inclusion criteria and therefore diverse patient groups; other 
treatment methods (i.e. hemiablation vs. focal ablation); and distinct definitions for functional 
outcomes and disease free survival. Furthermore, some studies lump functional outcomes 
along with complications instead of reporting objective validated questionnaire-based data. 
Preferably baseline, short-term and long-term urinary, sexual and bowel function should 
be ascertained utilizing patient-reported questionnaires. However, these instruments are 
underutilized and data are sparse. In our study these data were collected in most of the 
patients, yielding unique information.
 Proper patient selection is important when performing focal salvage therapy. In contrast 
to previous focal salvage studies, we also included patients with extracapsular extension 
and/or seminal vesicle invasion. This might have had a negative influence on our cancer 
control rate, because these patients have a higher chance of developing metastatic disease. 
Micrometastatic disease was probably present in five patients at the time of their MRI-
guided cryoablation, because they were diagnosed with metastatic disease within 6 months 
after treatment. This was not detected during pre-treatment imaging, probably because the 
current radiological work-up to detect distant metastases is not sensitive enough27. Recently, 
lymphotropic nanoparticle-enhanced MRI became available in our centre. This technique 
has shown high sensitivity (65-92%) and specificity (93-98%) in detecting PCa lymph node 
metastases27 and may improve our patient selection28.
 In this study mp-MRI was used to detect and localize clinically significant disease after 
radiotherapy. It has shown a 95% negative predictive value in detecting local recurrences29. 
Despite this, tumor could have been missed or treated incompletely, because it was not 
(completely) visible on the MR images.
 Currently, there is no consensus how to determine biochemical failure after salvage focal 
therapy30. Phoenix- and ASTRO-criteria were originally developed to define biochemical failure 
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after radiotherapy. They are not suitable and validated for use after focal therapy, because 
part of the prostate remains untreated and the mechanism of cell death is different between 
cryoablation and radiotherapy. Because of the absence of a validated definition, in this study 
Phoenix-criteria were used in combination with any clinical, radiological or histopathological 
evidence for local recurrent or metastatic disease to determine cancer control. Despite 
this combined approach influenced our cancer control rate in a negative way, we think it 
has surplus value, since 4 patients who did not had biochemical failure yet were diagnosed 
with recurrent disease after mp-MRI and targeted MRI-guided biopsy. For this reason we 
recommend to perform targeted biopsy of the rim of the ablation zone.
 Limitations of our study were the relative small number of patients, its retrospective 
design and incomplete follow-up. Although our results are encouraging, more patients are 
currently included and longer follow-up is performed. Unfortunately, our patient follow-up 
was not complete. In the start-up period of MRI-guided cryoablation, functional outcomes 
and complications were not systematically reported with validated disease-specific 
questionnaires in this patient group. This led to an incomplete follow-up and hampered an 
objective comparison in functional outcome and QoL before- and after treatment. This is 
also reason that not all patients underwent MRI-guided targeted biopsy of the area treated 
with cryoablation.
 Future steps will be to study which prognostic factors (i.e. PSA, stage, ADT use, etc) have 
influenced our outcome. This will improve the current patient selection methods and we 
might be able to determine the true value of this treatment for the right patient group. Next 
to this, trials combining MRI-guided cryoablation with adjuvant therapy or immunotherapy 
could be developed.
 In conclusion, focal salvage MRI-guided cryoablation is feasible and shows a positive balance 
between adverse events, functional outcome, QoL and cancer control. It may be a reasonable 
alternative to SRP in properly selected patients, however longer follow-up is needed.
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Fig 1 Study flow diagram
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Fig 1. Study flow diagram. 
Fig 2 Results validated questionnaires for functional outcome measured with the IPSS, IPSS-QoL, ICIQ-SF 
and IIEF-5 questionnaires. Plots show mean values (bars) with a 95% CI (whiskers). Two-tailed p-values were 
calculated comparing baseline and 12 month mean scores. * indicates p<0.05.
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Fig 2. Results validated questionnaires for functional outcome measured with the IPSS, IPSS-QoL, ICIQ-SF and IIEF-5 
questionnaires. Pl ts show mean valu s (bars) with a 95% CI (whisk rs). Two-t il d -values were calculated comparing 
baseline and 12 month mean scores. * indicates p<0.05. 
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Fig 3 Results for quality of life outcome measured with the FACT-P questionnaires. Plots show mean values 
(bars) with a 95% CI (whiskers). Two-tailed p-values were calculated comparing baseline and 12 month mean 
scores. * indicates p<0.05.
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Fig 3. Results for quality of life outcome measured with the FACT-P questionnaires. Plots show mean values (bars) with a 
95% CI (whiskers). Two-tailed p-values were calculated comparing baseline and 12 month mean scores. * indicates p<0.05. 
 
Fig 4 Kaplan-Meier curve for cancer control according to the Phoenix-criteria for biochemical disease free 
survival in combination with any clinical, radiological or histopathological evidence for local or recurrent disease.
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Fig 4. Kaplan-Meier curve for cancer control according to the Phoenix-criteria for biochemical disease free survival in 
combination with any clinical, radiological or histopathological evidence for local or recurrent disease. 
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Table 1. Baseline demographics (n=41) 
 Median (IQR) 
Age (y) 67.0 (64.0-72.0) 
Type of Radiotherapy  
External Beam Radiation Therapy 
Brachytherapy 
External Beam Radiation Therapy AND Brachytherapy 
 
25 (61.0%) 
15 (36.6%) 
1 (2.4%) 
Time between RT and MRI cryo (mo) 71.5 (51.3-95.0) 
Pre RT characteristics 
PSA (ng/mL) 
Gleason 
≤5 
6 
7 
8 
unknown 
Tumor stage 
T1c – T2 
T3 
unknown 
 
12.1 (7.1-20.1) 
 
4 (9.8%) 
15 (36.6%) 
12 (29.3%) 
8 (19.5%) 
2 (4.9%) 
 
19 (46.3%) 
19 (46.3%) 
3 (7.3%) 
Pre MRI cryo characteristics 
PSA (ng/mL) 
Gleason 
6 
7 
8 
9 
10 
unknown 
Tumor stage 
T2 
T3 
Prior ADT use 
 
4.1 (2.7-7.7) 
 
5 (12.2%) 
16 (39.0%) 
6 (14.6%) 
5 (12.2%) 
1 (2.4%) 
8 (19.5%) 
 
29 (70.7%) 
12 (29.3%) 
16 (39.0%) 
RT = Radiotherapy; PSA= Prostate specific antigen; ADT = Androgen deprivation therapy 
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Table 2 Procedure characteristics
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Table 2. Procedure characteristics 
 Median (IQR) 
Total anaesthetic time (min) 183.5 (165.0-208.0) 
Procedure time (min) 108.0 (95.0-126.0) 
Number of cryoneedles 3.0 (2.0-4.0) 
Hospitalization (days) 2.0 (1.0-2.0) 
 
 
  
Table 3 Complications classified according to the modified Clavien System for reporting surgical 
complications after the first MRI-guided cryoablation procedure (n=41)
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Table 3. Complications classified according to the modified Clavien System for reporting surgical complications 
after the first MRI-guided cryoablation procedure (n=41) 
Grade Definition  n (%) 
1 Any deviation from normal post-operative course 24 (58.5) 
2 Complications needing intravenous medication or antibiotics 4 (9.8) 
3a Complications needing intervention under local anesthesia 2 (4.9) 
3b Complications needing intervention under general anesthesia 1 (2.4) 
4a Life-threatening: Single organ dysfunction 1 (2.4) 
4b Life-threatening: Multiple organ dysfunction 0 (0) 
5 Death of the patient 0 (0) 
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Table 4. Results validated questionnaires for functional outcome and quality of life (n=32) 
 Baseline 6 mo.  
after treatment 
12 mo.  
after treatment 
Baseline  
vs. 12 mo. 
 Mean  
(95%CI) 
Mean  
(95%CI) 
Mean  
(95%CI) 
 p- value 
(95%CI for 
difference) 
IPSS 9.4  
(7.0 – 11.7) 
9.7  
(6.7 – 12.6) 
10.1  
(7.7 – 12.5) 
0.595 
(-2.0 – 3.4) 
IPSS-QoL 1.8  
(1.4 – 2.1) 
1.8  
(1.4 – 2.2) 
1.9  
(1.5 – 2.3) 
0.532 
(-0.4 – 0.7) 
ICIQ-SF  1.6  
(0.6 – 2.7) 
4.6  
(3.1 – 6.1) 
4.7  
(3.1 – 6.4) 
*0.001 
(1.3 – 4.9) 
IIEF-5 10.8  
(7.7 – 13.9) 
9.9  
(7.3 – 12.4) 
7.7  
(5.4 – 10.0) 
*0.024 
(-5.9 – -0.5) 
FACT-P 130.8  
(126.6 – 135.1) 
126.2  
(119.8 – 132.7) 
126.3  
(120.0 – 132.5) 
0.101 
(-10.2 – 1.0) 
FACT-G 92.3  
(89.1 – 95.5) 
89.2  
(84.1 – 94.4) 
90.4  
(86.0 – 94.9) 
0.263 
(-5.3 – 1.5) 
TOI 88.6  
(85.5 – 91.7) 
85.7 
(81.3 – 90.1) 
85.4  
(81.4 – 89.4) 
0.118 
(-7.2 – 0.9) 
*statistically significant 
 
Table 4 Results validated questionnaires for functional outco e and quality of life (n=32)
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CHAPTER 7
ABSTRACT
OBJECTIVES
To evaluate ice-ball margins after magnetic resonance (MR)-guided focal salvage prostate 
cryoablation and determine the correlation with local outcome.
METHODS
A retrospective review was performed on forty-seven patients that underwent percutaneous 
MR-guided focal cryoablation for biopsy-proven locally recurrent prostate cancer after primary 
radiotherapy. Preprocedural diagnostic and intraprocedural MR images were analyzed to 
derive three-directional ice-ball margins. Local tumor progression after cryoablation was 
defined as evident tumor recurrence on follow-up MRI, positive MR-guided biopsy or 
biochemical failure without radiological evidence of metastatic disease.
RESULTS
Mean ice-ball margins were 8.9 mm (range: -7.1-16.2), 10.1 mm (range: 1.1-20.3) and 12.5 
mm (range: -1.5-22.2) in antero-posterior, left-right and cranio-caudal direction respectively. 
Ice-ball margins were significantly smaller for tumors that were larger (P=.008) or located in 
the posterior gland (P=.047). Significantly improved local progression free survival at 1-yr post 
focal cryoablation was seen between patients with ice-ball margin >10 mm (100%), 5-10 mm 
(84%) and <5 mm (15%) (P<.001).
CONCLUSIONS
Ice-ball margins appear correlated with local outcome following MR-guided focal salvage 
prostate cryoablation. Our initial data suggest that freezing should be applied at minimum 
5-mm beyond the border of an MR-visible recurrent prostate tumor for successful ablation, 
with a wider margin appearing desirable.
119
ICE-BALL MARGINS AFTER FOCAL SALVAGE MR-GUIDED PROSTATE CRYOABLATION
INTRODUCTION
Prostate cancer (PCa) recurrence following radiotherapy (RT) is not uncommon, with an 
estimated 10-60% of patients experiencing biochemical failure within 5 to 10 years after 
treatment1,2. There has been no consensus on optimal management of this patient group 
with a majority of patients receiving androgen deprivation therapy (ADT)3. Treatment options 
with curative intent are limited and include salvage radical prostatectomy (RP), brachytherapy, 
high-intensity focused ultrasound and cryoablation4.
 Salvage RP is generally regarded as a challenging procedure to perform and has been 
associated with high complication risks5. Whole-gland salvage cryoablation has emerged as 
an accepted treatment alternative, with acceptable oncological outcomes and side-effects6,7. 
However, complications such as erectile dysfunction (72-100%), incontinence (2.6-73%) and 
rectal fistula (0-3.4%) may still exist8,9. In an attempt to reduce treatment morbidity, several 
studies have been exploring the concept of partial cryoablation for biopsy-proven unilateral 
recurrences9–11. At the same time, advancements in prostate magnetic resonance (MR) imaging 
have enabled the accurate detection and localization of locally recurrent PCa after previous 
irradiation12,13. Additionally, MRI can also be used to intraoperatively guide cryoablation 
procedures14,15, opening new possibilities for focal salvage approaches.
 In a recent study the feasibility of MR-guided focal cryoablation was shown in ten patients 
with locally recurrent PCa after primary RT16. Although initial short-term results were 
promising, three patients developed local tumor recurrence at the site of ablation within six 
to twelve months after treatment and the authors concluded that these tumors were most 
probably undertreated. Findings from in vitro and in vivo animal studies on renal cryoablation 
have shown that lethal temperatures may be achieved at approximately 5-6 mm within the 
edge of the ice-ball17,18. For prostate cryoablation, some authors have suggested freezing to 
be applied 2-3 mm beyond the tumor boundary to reach an end temperature of -20°C, which 
has been associated with tissue necrosis19. However, limited clinical data is presently available 
verifying these recommendations with patient outcomes and a consensus on the margin 
needed for effective cryoablation of recurrent PCa has not been established. The purpose 
of the present study was to evaluate ice-ball margins after MR-guided focal salvage prostate 
cryoablation and determine the correlation with local outcome.
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MATERIALS AND METHODS
In July 2016, a total of 61 consecutive patients were identified that underwent MR-guided focal 
cryoablation for locally recurrent PCa at our institution between May 2011 and July 2015 and 
were ≥1-yr after treatment. Ten patients were excluded because they had undergone previous 
salvage treatment. Additionally, three patients who underwent radical prostatectomy as 
primary treatment and one patient who was treated in two separate sessions were excluded. 
A total of 47 patients (median age 66 years, age range: 52-79) underwent MR-guided focal 
cryoablation for local PCa recurrence after primary RT and were included in this retrospective 
study. Informed consent to use anonymized data for analysis was obtained in all patients.
 Patients were eligible for focal cryoablation on the basis of biopsy-proven MRI visible 
local PCa recurrence without radiologic evidence of metastatic disease. The final decision to 
perform cryoablation was made on the multidisciplinary board meeting. Focal cryoablation 
was performed at a median of five years (range: 1-18) after primary RT. Prior to treatment, 
all patients underwent 3-T multi-parametric MR imaging (mpMRI) with a pelvic phased-array 
coil (n=43) or endorectal coil (n=4), consisting of T2-weighted (T2w), diffusion-weighted (DWI) 
and dynamic contrast-enhanced (DCE) imaging, to localize the recurrence and measure visible 
tumor volume as well as an abdominal and pelvic staging MRI to exclude nodal or bone 
marrow metastases. There were no restrictions related to pre-treatment prostate specific 
antigen (PSA) level, Gleason score, prior history of ADT, tumor volume or local extent. The 
National Comprehensive Cancer Network (NCCN) guidelines were used to categorize patients 
into low-to-intermediate and high-risk groups20. High-risk status was assigned when any of 
the following criteria was met: cancer stage ≥T3a, Gleason ≥8 or PSA ≥20 ng/ml. A summary 
of patient demographics is included in Table 1.
CRYOABLATION PROCEDURES
Patients were treated under general anesthesia in a 1.5-T or 3-T MR system (Magnetom 
Avanto or Skyra, Siemens, Erlangen, Germany). All procedures were performed by one of two 
interventional radiologists (J.F. or S.J.) each with more than 6 years of experience in prostate 
interventions. A urethral warming catheter and rectal balloon were inserted to protect the 
urethra and rectal wall. Using a transperineal approach, multiple MR-compatible cryoprobes 
(MRI IceSeed or IceRod, Galil Medical, Yokneam, Israel) were placed centrally in the target 
region under real-time MR image guidance. Type, number and position of cryoprobes were 
chosen at the discretion of the performing physician. Cryoablation was performed using 
an MR-compatible cryoablation device (MRI-SeedNet; Galil Medical, Yokneam, Israel). Two 
10-min. freezing cycles separated by 2-min. passive and 1-min. active thaw were applied 
under continuous T1-weighted gradient echo MR monitoring21,22. Using the intraprocedural 
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images, the size and shape of the ice-ball were modulated by regulating the gas flow to each 
individual cryoprobe such as to cover the entire tumor while avoiding ice-ball contact to 
the rectal wall. Upon completion of the ablation, all cryoprobes were thawed and removed. 
All intraprocedural complications were documented. Post-procedural complication data, 
functional outcomes and quality-of-life metrics were not part of the present work and will 
be reported elsewhere.
IMAGE REVIEW AND FOLLOW-UP
All preprocedural and intraprocedural images were retrospectively reviewed by one prostate 
interventional radiologist (S.J.) using medical image visualization software (MeVisLab, 
Fraunhofer, Bremen, Germany). Treated tumors were annotated on the pre-treatment 
diagnostic mpMRI using information from all available MR sequences to delineate the tumor 
boundary. Tumor locations were classified as anterior when located for >50% in the ventral 
half of the prostate or posterior when located >50% in the dorsal half of the prostate.
 Intraprocedural MR images obtained at the end of the second freeze cycle were used 
to annotate each corresponding ice-ball. Using MeVisLab software, each annotated ice-ball 
was registered to the center of the corresponding annotated tumor. Maximum tumor and 
corresponding ice-ball sizes were derived from the annotated regions in antero-posterior, 
left-right and cranio-caudal direction as well as total tumor and ice-ball volumes. The ice-ball 
margin was then defined as the margin calculated by subtracting the ice-ball’s radius from 
the corresponding lesion radius in each direction (Figure 1). The minimum ice-ball margin 
was defined as the shortest margin in each patient. Undertreated tumors were defined by a 
negative margin between the ice-ball and tumor. Finally, the position of the ice-ball relative 
to the tumor was recorded: a well-centered ice-ball covered the entire tumor in the axial 
plane at the center of the lesion.
 Post-procedural follow-up (median 24 months, range: 3–42) consisted of regular urology 
visits with PSA monitoring at 1, 3, 6, 9 and 12 months after treatment, followed by 3-6 
month intervals. In addition, all patients underwent follow-up prostate mpMRI at 3, 6 and 
12 months after treatment. All follow-up images were reviewed by one of two prostate 
interventional radiologists (J.F. and S.J.). Any finding suspicious for residual or recurrent tumor 
was subsequently sampled by targeted in-bore MR-guided biopsy. Furthermore, all patients 
received targeted in-bore MR-guided biopsy directed at the ablation zone at 12 months post-
treatment from October 2013 onwards. Local tumor progression after focal cryoablation 
was defined as evident tumor recurrence on follow-up MRI,  positive MR-guided biopsy or 
biochemical failure according to Phoenix criteria of PSA nadir + 2 ng/ml23 without radiological 
evidence of metastatic disease.
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STATISTICAL ANALYSIS
Statistics were performed using SPSS (Version 20.0). Data are reported as mean±standard 
deviation unless indicated otherwise. Baseline parameters were compared between cases of 
local control and tumor progression using independent samples T-test for normally distributed 
and Mann-Whitney U-test for non-normally distributed data. Chi-square analysis was used 
for discrete data. Independent samples T-test was used to compare ice-ball margins by tumor 
volume and location. Survival analysis was performed using the Kaplan-Meier method. Log-
rank test was used to assess differences between survival curves. Cox proportional hazard 
univariable and multivariable models were used to assess pre-treatment risk status, prior ADT 
use and tumor volume as potential confounders and determine whether ice-ball margins were 
independently associated with local progression. Potential prognostic factors with a P-value 
less than <.10 on univariable analysis were included in the multivariable model. Outcomes 
were reported as hazard ratios (HR) with 95% confidence intervals (CI)  to demonstrate level 
of precision. P-values <.05 were considered statistically significant.
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RESULTS
A total of forty-seven cryoablation procedures were successfully performed in 47 patients. A 
median of three cryoprobes (range: 2–6) were used per patient. The median ice-ball volume 
was 27.7 ml (range: 6.0–82.5). There were no intra-procedural complications. The median PSA 
nadir after focal prostate cryoablation was 0.6 ng/ml (range: <0.02–40.0) and was reached at 
a median of 3 months (range: 1–24) after treatment.
 On follow-up, twenty-four of 47 patients (51%) were locally controlled. Local tumor 
progression occurred in 23 patients (49%), of whom fourteen had a positive MR-guided 
prostate biopsy, seven experienced PSA failure without radiological evidence of distant disease 
and two patients had evident tumor recurrence on follow-up MRI but were excepted from 
targeted biopsy due to detection of nodal or bone metastases on the same scan. The median 
time between treatment and local tumor progression was twelve months (range: 3–42). 
After multidisciplinary consensus seven patients with local tumor progression received repeat 
treatment with MR-guided cryoablation. 10/47 patients (21%) showed metastatic disease 
progression, of whom six were locally controlled and four patients also had evidence of local 
tumor progression.
 Distribution of baseline parameters between cases of local control and tumor progression 
is shown in Table 2. A statistically significant difference was found in prior history of ADT 
administration between the stable and local progression group (5/24 vs. 11/23; P=.025). No 
difference was seen for pre-treatment PSA level, Gleason score and clinical stage.
ICE-BALL MARGINS
The mean ice-ball margins for focal cryoablation were 8.9 mm (range: -7.1–16.2), 10.1 mm 
(range: 1.1–20.3) and 12.5 mm (range: -1.5–22.2) in antero-posterior, left-right and cranio-
caudal directions respectively. The mean minimum ice-ball margin per patient was 7.5 mm 
(range: -7.1–14.2), with the shortest margin most often occurring in antero-posterior direction 
(49%). An ice-ball margin >5 mm in each direction was achieved in 34/47 (72%) of patients. 
Negative margins occurred in three cases (6%). Ice-balls were well-centered in all but one 
patient. The one off-center ice-ball occurred in a large tumor involving the peripheral zone 
and seminal vesicles. The ice-ball was found to be off-center on retrospective review of the 
intraprocedural images because the insertion angle of the cryoprobes was incorrectly aligned 
with the tumor’s geometry, causing the ice-ball to be off-center at the prostatic base and 
seminal vesicles.
 When stratified by tumor volume and location, the average minimum ice-ball margin was 
significantly smaller for tumors >1 ml compared to tumors ≤1 ml (5.8±4.8 vs. 9.2±3.4 mm; 
P=.008) (Figure 2) and for posterior versus anterior tumors (6.8±4.7 vs. 9.8±2.7 mm; P=.047) 
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(Figure 3).
 On Kaplan-Meier analysis, significantly improved local tumor progression free survival at 
1-yr after focal cryoablation was seen between patients with minimum ice-ball margin >10 
mm (100%), 5-10 mm (84%) and <5 mm (15%) (P<.001) (Figure 4). Representative cases with 
and without local tumor progression after focal salvage cryoablation are shown in Figure 5 
and 6 respectively. Univariable and multivariable Cox regression analysis is shown in Table 
3. Minimum ice-ball margin (P<.001), tumor volume (P=.005) and prior ADT use (P=.014) 
showed significant association with local outcome on univariable analysis. On multivariable 
analysis, minimum ice-ball margin (P=.004) and prior ADT use (P=.008) remained independent 
predictors of local tumor progression.
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DISCUSSION
The concept of focal therapy is to treat a tumor focus with an adequate margin while sparing 
as much surrounding healthy tissue as possible24. In cryoablation, the lethal temperature 
threshold is generally regarded to lie between -20°C to -40°C, depending on freezing rate, 
freeze duration and the repetition of freeze-thaw cycles25. With lethal temperatures residing 
several millimeters behind the leading edge of the freezing process26, it is imperative to achieve 
a definitive margin with sufficient ice extending beyond the tumor border to ensure effective 
tissue necrosis throughout the entire target region. For renal cryoablation, studies have 
recommended freezing to be applied for approximately 5 to 6 mm beyond the tumor border 
to achieve suitably cold end temperatures18,27,28. In contrast, another study suggested that for 
liver cryoablation with a single cryoprobe a margin up to 1 cm might not be sufficient29, but the 
synergistic effect of multiple cryoprobes was not studied26,30. Furthermore, it is unclear how 
findings from other areas of application, i.e. renal or liver cryoablation, apply to the prostate 
salvage setting. Adding to this, uncertainty exists in predicting tumor borders from MRI with 
respect to the true histological tumor boundary. For primary PCa, one study has recently 
shown that imaging-derived tumor boundaries from prostate mpMRI tend to underestimate 
the histologically determined tumor volume at prostatectomy31. The authors concluded that 
a treatment margin extending 9 mm around an MRI visible tumor would be required to 
ensure treatment of the complete tumor volume during focal ablative therapy32. A similar 
study investigating the accuracy of MR-based prostate tumor delineations for radiotherapy 
planning recommended a margin of 5 mm to achieve adequate coverage33. In the present 
work, MR imaging-derived ice-ball margins were correlated with local outcome after focal 
salvage prostate cryoablation. A high rate of early local tumor progression (85% at 1-yr) was 
noted when the ice-ball margin around an MRI visible recurrent prostate tumor were less 
than 5 mm. These initial clinical data suggest that a minimal 5-mm margin would be required 
for effective focal salvage prostate cryoablation, with a wider margin appearing desirable.
 A notable finding was that the ice-ball margins varied significantly with tumor location. In 
the posterior area of the prostate it can be particularly challenging to achieve sufficient ice 
coverage extending beyond the tumor boundary due to its close proximity to the rectum. 
During ablation, adjacency of the ice ball to the rectal wall was actively monitored in the 
intraoperative MR images and freeze intensity was modulated accordingly in order to avoid 
unwanted damage to the rectal wall. Also, the rectum was actively warmed with warm saline 
using a rectal balloon, which may explain the lower ice-ball margins achieved in posterior 
tumors. For these tumor localizations, critical pre-operative assessment of the ability to 
achieve adequate ablation margins should be performed in each individual case. Additionally, 
displacement of the rectum using hydrodissection may be considered to obtain increased 
spacing between the prostate and rectal wall and allow for a wider ablation margin.
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 There also was a significant difference in the average ice-ball margin depending on tumor 
volume. However, substantial overlap can be seen between the margins achieved in the larger 
(>1 ml) and smaller (<1 ml) lesions and successful ablations were achieved in tumors up to 3.3 
ml in volume when a 5-mm margin was achieved. Likewise, local tumor progression occurred 
after ablation of lesions as small as 0.3 ml when the margin was insufficient in one direction. 
Together, these findings suggest that even though it is more difficult to achieve wide ablation 
margins in larger tumors, successful ablation can be achieved. In addition, in small tumors, 
the need for an adequate ice-ball margin remains important.
 Of baseline parameters, prior history of ADT use was significantly different between 
cases of local control and tumor progression and demonstrated significant association with 
local tumor progression on multivariate analysis as well. Although large randomized studies 
have shown ADT to improve cancer-specific and overall survival when given neoadjuvantly 
to primary radiation34,35, the exact role of ADT before salvage treatment has not been well 
defined. An early study has investigated the effect of the combination of androgen deprivation 
with salvage surgery in patients with radiorecurrent prostate cancer and suggested patients 
in whom an initial trial of ADT failed to be poor candidates for salvage prostatectomy36. 
Similarly, for whole-gland salvage prostate cryoablation one study has recently shown that 
patients receiving ADT before salvage cryoablation had worse 5-yr biochemical progression 
free survival37. One explanation is that the initiation of ADT before salvage cryoablation may 
have concealed rising PSA levels, masking micrometastatic disease progression. Consequently, 
at the time of salvage cryoablation patients with systemic disease may be unintentionally 
subjected to local salvage treatment.
 Possibly, the latter is corroborated by the substantial proportion of patients diagnosed 
with metastatic disease progression during follow-up of the present study (21%). All but 
two of these instances occurred within the first 12 months after focal salvage treatment and 
metastatic work-up may have been false negative in these patients, with current imaging 
techniques having limited sensitivity38. Improved metastatic screening using new contrast 
agents such as iron nanoparticles-enhanced MR lymfography38,39 or Gallium 68-PSMA PET-
CT40 to specifically evaluate lymph node status may be imperative to better select suitable 
candidates for local salvage treatment.
 The most important limitation of our study was that ice-ball margins were only calculated 
in three directions and assumed the ice-ball to be well-centered with respect to the tumor 
to register the annotated regions. In some patients, margins may not necessarily have been 
symmetrical and there could be a sufficient margin on one side but an insufficient margin on 
the other side when a tumor was not centrally located within the ablation zone. Ideally, all 
pre-treatment images would be exactly matched to the intraprocedural data to provide an 
improved assessment of the 3D ablation margin. To our experience however, direct registration 
of the image sets will not necessarily be accurate due to prostate deformation from cryoprobe 
insertion or movement of the entire gland due to the rectal balloon and adequate methods 
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to address these errors are needed to provide a more detailed characterization of the true 
ablation margin in future studies.
 Other limitations to this work include its retrospective nature and short to intermediate 
term follow-up. Also, there is currently no universally accepted definition of tumor recurrence 
following local prostate salvage treatments. The Phoenix definition is the most commonly 
reported criterion in this setting and in one study was found to more accurately predict local 
cancer recurrence following prostate cryoablation than American Society for Therapeutic 
Radiotherapy and Oncology (ASTRO) criteria41. Imaging follow-up of the prostate after focal 
therapy using mpMRI has also been increasingly applied, with functional techniques showing 
promise to detect local PCa recurrence after therapy42. In this study, both biochemical as well 
as mpMRI and biopsy findings were integrated into a combined definition of local tumor 
progression. Ultimately, a standardized definition would need to be identified to facilitate direct 
comparison of studies evaluating prostate focal ablation techniques. Finally, heterogeneity 
can be seen in our patient cohort with respect to pre-salvage PSA levels, Gleason scores and 
clinical stage. Our findings require validation on multivariable analysis in more patients and 
with longer follow-up to come to definitive conclusions.
 In conclusion, ice-ball margins appear correlated with local outcome following MR-guided 
focal salvage prostate cryoablation. Our initial data suggest that a margin of at minimum 5 
mm should be achieved around an MR-visible recurrent tumor for successful ablation, with a 
wider margin being desirable. Adequate margins may be more difficult to achieve in tumors 
that are larger and located posteriorly, which may be an important factor to consider when 
selecting candidates for focal salvage treatment after previous RT.
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FIGURES
Fig 1 Annotation of (A) tumor (outlined in white) on pre-treatment axial and sagittal T2-weighted, ADC and DCE 
prostate MR images and (B) corresponding ice-ball (outlined in white) at the end of the second freeze cycle on 
axial and sagittal intraprocedural T1-weighted images, with urethral warming catheter in situ (arrowhead). (C) 
The ice-ball margin (asterisk) was determined by subtracting the radii of the tumor (yellow) and ice-ball (blue) 
along each direction.
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Fig 1. Annotation of (A) tumor (outlined in white) on pre-treatment axial and sagittal T2-weighted, ADC and DCE prostate 
MR images and (B) corresponding ice-ball (outlined in white) at the end of the second freeze cycle on axial and sagittal 
intraprocedural T1-weighted images, with urethral warming catheter in situ (arrowhead). (C) The ice-ball margin (asterisk) 
was determined by subtracting the radii of the tumor (yellow) and ice-ball (blue) along each direction. 
  
Fig 2 Minimum ice-ball margin stratified by tumor volume.
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Fig 2. Minimum ice-ball margin stratified by tumor volume. 
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Fig 3 Minimum ice-ball margin by anterior or posterior tumor locations.
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Fig 3. Minimum ice-ball margin by anterior or posterior tumor locations. 
  
Fig 4 Local progression free survival stratified by minimum ice-ball margin 
<5 mm, 5-10 mm and >10 mm, with corresponding numbers at risk.
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Fig 4. Local progression free survival stratified by minimum ice-ball margin <5 mm, 5-10 mm and >10 mm, with 
corresponding numbers at risk. 
  
130
CHAPTER 7
Fig 5 Representative case of local tumor progression after MR-guided focal salvage cryoablation. (A) 
Pre-treatment axial T2-weighted, ADC and DCE images show a hypointense lesion with diffusion restriction 
and focal enhancement in the prostatic base extending into the seminal vesicles after primary radiotherapy. 
Local PCa recurrence was histologically confirmed with in-bore MR-guided biopsy. Annotated tumor boundary 
is overlaid (white outline). (B) Corresponding intraprocedural axial T1-weighted image during MR-guided 
cryoablation shows the final frozen zone at the end of the second freeze cycle, with annotated ice-ball boundary 
overlaid (white outline). Urethral warming catheter is indicated (arrowhead).  (C) 12 month follow-up MRI 
shows hypointense signal on axial T2-weighted images with diffusion restriction and focal enhancement in the 
seminal vesicles. Local recurrence after cryoablation was confirmed on targeted in-bore MR-guided biopsy. (D) 
Retrospective review of this case showed a minimum ice-ball margin of -7.1 mm, with insufficient coverage in 
antero-posterior direction.
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second freeze cycle, with annotated ice-ball boundary overlaid (white outline). Urethral warming catheter is indicated 
(arrowhead).  (C) 12 month follow-up MRI shows hypointense signal on axial T2-weighted images with diffusion restriction 
and focal enhancement in the seminal vesicles. Local recurrence after cryoablation was confirmed on targeted in-bore MR-
guided biopsy. (D) Retrospective review of this case showed a minimum ice-ball margin of -7.1 mm, with insufficient 
coverage in antero-posterior direction. 
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Fig 6 Representative case of local tumor control. (A) Pre-treatment axial T2-weighted, ADC and DCE images 
demonstrate a histologically confirmed local PCa recurrence with diffusion restriction and focal enhancement 
in the ventral transition zone (white outline) after primary brachytherapy. (B) Intraprocedural axial T1-weighted 
image shows the final frozen zone (white outline) at the end of the second freeze cycle, with urethral warming 
catheter indicated (arrowhead). (C) 12 month follow-up MRI shows hyperintense signal on axial T2w images 
without diffusion restriction at the ventral transition zone. DCE images show a non-perfused area at the same 
location that coincides with the treated area. Targeted in-bore MR-guided biopsy directed at the ablation area 
showed no evidence of malignancy. (D) The retrospective review of this case showed adequate coverage in all 
directions, with the minimum ice-ball margin being 9.4 mm.
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Fig 6. Representative case of local tumor control. (A) Pre-treatment axial T2-weighted, ADC and DCE images demonstrate a 
histologically confirmed local PCa recurrence with diffusion restriction and focal enhancement in the ventral transition zone 
(whit  outli e) af r primary br chytherapy. (B) Intrapr cedural axial T1-weight d image shows the final frozen zone (white 
outline) at the end of the second freeze cycle, with urethral warming catheter indicated (arrowhead). (C) 12 month follow-
up MRI shows hyperintense signal on axial T2w images without diffusion restriction at the ventral transition zone. DCE 
images show a non-perfused area at the same location that coincides with the treated area. Targeted in-bore MR-guided 
biopsy directed at the ablation area showed no evidence of malignancy. (D) The retrospective review of this case showed 
adequate coverage in all directions, with the minimum ice-ball margin being 9.4 mm.  
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TABLES
Table 1 Patient demographic data (n=47)
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Table 1. Patient demographic data (n=47) 
 Median (range) or n (%) 
Age (y) 66 (52–79) 
PSA level (ng/ml) 4.9 (0.7–31.0) 
Form of primary RT  
EBRT 29 (62) 
Brachytherapy 17 (36) 
EBRT + Brachytherapy 1 (2) 
Time to recurrence since primary RT (y) 5 (1-18) 
Prior ADT use  
Yes 17 (36) 
No 30 (64) 
Gleason score of recurrence  
≤6 7 (15) 
7 17 (36) 
≥8 16 (34) 
Unknown or undeterminable 7 (15) 
Clinical stage  
T2a-c 35 (69) 
T3b 12 (31) 
NCCN risk category  
Low-to-intermediate 18 (38) 
High 29 (62) 
Prostate volume (ml) 23.5 (6.6–64.2)  
Tumor localization  
Transition zone 11 (23) 
Peripheral zone and/or seminal vesicles 36 (77) 
Tumor volume (ml) 1.1 (0.2–11.8) 
External beam radiotherapy (EBRT); Androgen-deprivation therapy (ADT); National Comprehensive Cancer 
Network (NCCN). 
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Table 2 Comparison of baseline parameters
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Table 2. – Comparison of baseline parameters 
 Local control (n=24) 
Local progression 
(n=23) P-value 
PSA level 6.8 (0.7–31.0) 7.1 (1.1–21.0) .566 
Gleason score 
≤7 
>7 
Unknown 
 
14 (58) 
8 (33) 
2 (8) 
 
10 (43) 
8 (35) 
5 (22) 
.604 
Clinical stage 
T2a-c 
T3b 
20 (83) 
4 (17) 
15 (65) 
8 (35) 
.154 
Prior ADT use 
Yes 
No 
5 (21) 
19 (79) 
11 (48) 
12 (52) 
.025 
 
Values in parentheses are range or percentages 
  
Table 3 Cox regression analysis of predictors of local progression
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Table 3. – Cox regression analysis of predictors of local progression 
 Univariable   Multivariable  
 HR (95% CI) P-value  HR (95% CI) P-value 
Min. ice-ball margin 0.85 (0.78–0.93) <.001  0.85 (0.77–0.95) .004 
Tumor volume 1.25 (1.07–1.45) .005  1.08 (0.91–1.28) .40 
Prior ADT use 0.35 (0.15–0.81) .014  0.30 (0.12–0.73) .008 
NCCN risk category 1.67 (0.70–3.97) .25  -  
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SUMMARY
In this thesis, recent advances in MR-guided prostate interventions were presented and its 
applications were assessed in the clinic.
 In chapter 2, it was shown that based on the current literature in-bore MR-guided prostate 
biopsy can be regarded as a safe and accurate tool to detect clinically significant prostate 
cancer, achieving high diagnostic performance using less biopsy cores than traditional TRUS-
guided biopsy. Current limitations of in-bore biopsy are its long procedure times, limited 
general availability and costs, which may restrict clinical applicability of the technique to 
selected patients.
 Chapter 3 introduced a novel targeting method to potentially accelerate in-bore prostate 
biopsy procedures and evaluated its feasibility during transrectal 3-T in-bore MR-guided 
prostate biopsy. Twenty patients with one cancer suspicious region (CSR) with PI-RADS score 
≥4 on diagnostic multiparametric MRI were prospectively enrolled. Targeting of the CSR was 
performed under real-time MR imaging displayed on a tablet device inside the MR-room. 
Feasibility and technical success of the targeting method were assessed. Also, biopsy and 
procedure times were recorded and compared against a matched reference cohort that 
had underwent the current routine biopsy procedure. Real-time targeting was found to be 
technically successful in all patients and allowed sampling of each CSR without requiring 
additional needle guide adjustment in 19/20 (95%) lesions. Also, initial clinical experience 
indicated a substantial reduction of the mean total procedure time (30%) compared to the 
current biopsy procedure.
 In chapter 4 the temperature dependency of T1-weighted MR image contrast around a 
cryoablation ice-ball was investigated as a potential tool to monitor thermal variations in 
the tissue directly adjacent to the frozen zone. Cryoablation experiments were performed 
in phantoms (n=3) under continuous MR monitoring using a T1-weighted gradient echo 
sequence. Normalized signal intensity was related to temperatures measured using 
fiberoptic probes. The same sequence was used during MR-guided prostate cryoablation 
in 10 consecutive patients and in vivo signal variations were quantitatively compared to the 
phantom data. The cryoablation ice-ball presented in the T1-weighted images as a signal void 
surrounded by a hyperintense rim. The hyperintense rim was found to correspond to cooled 
but non-freezing temperatures (<20°C) in tissue proximal to the frozen zone. The same image 
contrast was observed both in a phantom study as well as in vivo in the human prostate (root 
mean square difference between the normalized signal curves 0.06). The monitoring of this 
rim could potentially be useful to maintain a safe margin from at-risk tissues during MR-guided 
prostate cryoablation procedures.
 In chapter 5, the potential of 3D UTE imaging to obtain MR signal from frozen tissue 
and measure the temperature distribution within the cryoablation ice-ball was assessed. 
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Cryoablation experiments (n=4) were performed in ex-vivo porcine muscle specimens. The 
first three experiments were used as a reference set. UTE MR signal intensity was related to 
temperature measured by fiberoptic probes and fitted by a mono-exponential decay curve 
to obtain a calibration curve. The calibration curve was used to generate 3D MR temperature 
maps of the frozen tissue in the fourth experiment, as a validation set. Statistical analysis was 
performed to assess accuracy of the predicted MR temperature maps. We found 3D UTE 
imaging to obtain measurable MR signal from frozen tissue down to temperatures as low as 
-40°C. Temperatures predicted from the MR temperature maps strongly correlated with sensor 
recorded values with a mean difference of -1.2°C (+4.1 to –6.5). This work demonstrated the 
feasibility of 3D UTE MR thermometry of frozen tissue during cryoablation on a clinical MR 
system at 3-T. Down to -40°C, accuracy of the MR temperature maps was within clinically 
acceptable limits.
 The initial clinical results of application of focal MR-guided cryoablation in patients with 
locally recurrent prostate cancer after primary radiotherapy were presented in chapter 6. 
A retrospective, single-center study was performed in 41 patients with radiation-recurrent 
PCa who underwent MRI-guided cryoablation since May 2011 and had a follow-up of ≥12 
months. Feasibility and adverse events were reported. Validated questionnaires were used 
to observe pre- and post-treatment functional outcomes and quality-of-life. Cancer control 
was also evaluated and defined as no biochemical failure according to Phoenix-criteria and 
no other clinical, radiological or histopathological evidence for local or metastatic disease. 
All procedures were found to be technically feasible. There was one Clavien-grade 4 and one 
Clavien-grade 3b complication. At 12 months after treatment, symptoms of incontinence and 
erectile dysfunction became significantly worse compared to the pre-treatment scores, but 
quality-of-life was not significantly compromised. After 12 months, 23 patients (59%) were 
disease free. Overall, it was shown that focal salvage MR-guided cryoablation is feasible and 
shows an acceptable balance between adverse events, functional outcome, quality-of-life and 
local cancer control in this patient group. This treatment may be a reasonable alternative to 
salvage radical prostatectomy in carefully selected patients, but more data is needed.
 Chapter 7 evaluated ice-ball margins after MR-guided focal salvage prostate cryoablation 
and determined the correlation with local outcome. A retrospective study was performed on 
47 patients that underwent percutaneous MR-guided focal cryoablation for biopsy-proven 
locally recurrent prostate cancer after primary radiotherapy. Preprocedural diagnostic and 
intraprocedural MR images were analyzed to derive three-directional ice-ball margins. Local 
tumor progression after cryoablation was defined as evident tumor recurrence on follow-
up MRI, positive MR-guided biopsy or biochemical failure without radiological evidence of 
metastatic disease. Ice-ball margins were found to be significantly smaller for tumors that 
were larger or located in the posterior gland. Also, significantly improved local outcome at 
1-yr post focal cryoablation was seen between patients with ice-ball margin >10 mm (100%), 
5-10 mm (84%) and <5 mm (15%). Our initial data suggest that freezing should be applied at 
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minimum 5-mm beyond the border of an MR-visible recurrent prostate tumor for successful 
ablation, with a wider margin appearing desirable.
 Finally, it is concluded in chapter 8 that MR-guided biopsy is currently the most accurate 
targeted prostate biopsy technique but its clinical applicability may be restricted to selected 
patients. New, faster targeting techniques, however, may broaden its use. Furthermore, MR-
guided focal cryoablation presents a viable treatment option for localized prostate cancer 
recurrence after previous radiotherapy but careful patient selection is important.
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DISCUSSION
MR IMAGE-GUIDANCE AND INTERVENTIONAL MRI
Minimally invasive image-guided interventions have found wide-spread use during the last 
decades, with applications in soft-tissue biopsy and percutaneous tumor ablations in various 
organs. MR imaging is increasingly used to guide these diagnostic or therapeutic interventions1. 
MRI offers some unique advantages over conventional modalities such as ultrasound (US) or 
computed tomography (CT) for image guidance and monitoring of interventional procedures1,2. 
MRI has superb soft-tissue contrast for tumor visualization, provides near real-time imaging 
in arbitrary scan planes and allows functional imaging capabilities without ionizing radiation. 
Furthermore, MRI allows the evaluation of therapy-induced tissue changes and can be used 
to non-invasively measure tissue temperature during ablative therapy.
 Applications of interventional MR image-guidance range from intraoperative use during 
surgical procedures, such as minimally invasive neuro-, pediatric or breast surgery3,4, to 
guidance of soft-tissue biopsy and thermal ablation procedures in the lung, liver, kidney, 
prostate, brain and musculoskeletal system5–8. Inherently however, MRI also comes with some 
limitations with respect to its application in interventional image-guidance. One of these 
are the safety aspects associated with the MR environment. The magnetic field should be 
taken into account and prohibits use of unmodified electrical devices and ferromagnetic 
instruments in the MRI suite. Furthermore, specialized equipment is required for patient 
monitoring. The use of MRI for needle interventions is inherent to additional challenges such 
as magnetic susceptibility artefacts and the use of MR-compatible materials. Instruments 
should be designed such that they are non-ferromagnetic but still possess the mechanical, 
physical and/or electrical properties required for its specific application. Also, when using 
metallic guidewires or needles within the MR environment, these structures may be subject 
to radiofrequency (RF)-induced heating causing unwanted tissue damage. RF-heating is a 
complex phenomenon depending of many different factors, including magnetic field strength, 
pulse sequence specific RF power deposition and device geometry. Therefore, extensive 
instrument safety testing is required to ensure safe operating conditions. Finally, patient 
access may be restricted during MR-guided interventions compared with other guidance 
modalities, especially when a closed-bore MR system is used.
 Nevertheless, the unique benefits of MRI in guiding interventional procedures have 
motivated investigators to keep exploring potential applications of MR-guided interventions. 
Recent technological improvements and the increased availability of MR-compatible 
instruments and equipment have overcome some of the aforementioned issues and led to 
the development of new MR-guided minimally invasive strategies.
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MR-GUIDED PROSTATE BIOPSY
One such application that has rapidly evolved over the last several years is MR-guided prostate 
biopsy. In chapter 2, it was shown that based on the current literature in-bore MR-guided 
prostate biopsy can be regarded as a safe and accurate tool to detect clinically significant 
prostate cancer, achieving high diagnostic performance using less biopsy cores than traditional 
TRUS-guided biopsy. These advantages have led to a growing number of centers worldwide 
now performing this biopsy technique in the clinic. However, one important limitation of 
in-bore biopsy which currently restricts its clinical applicability are the long procedure times 
associated with this biopsy technique. In the present biopsy routine, needle guide adjustments 
are performed manually requiring the physician to walk in and out of the MR-scanner room 
followed by a subsequent imaging step to assess the current needle guide orientation. This 
cycle may require several iterations to reach the final biopsy target, which can be a time-
consuming process. In chapter 3 we proposed a novel targeting method using real-time 
imaging and a tablet device inside the MR-room. In a small patient study, it was shown that 
the proposed method has potential to substantially reduce the procedure time or MR-guided 
prostate biopsy.
 Another solution to speed up the biopsy procedure would be to automatically track the 
transrectal needle guide9. A phase-only cross correlation algorithm has been developed to 
automatically detect and track the needle guide during manipulation10. Subsequently, a fast 
imaging slice is aligned to continuously display the current needle guide orientation to the 
physician and assist in directing the needle guide towards the biopsy target. Furthermore, 
MR-compatible robotics have been developed that enable the needle guide to be manipulated 
from outside the MR-suite. Such a solution would obviate the need for the physician to walk 
in and out of the scanner room for needle guide repositioning and the potential of this robot-
assisted approach to in-bore biopsy has recently been shown in a few patient studies11–13. In 
the future, an integrated solution that combines the above techniques may be promising to 
effectively reduce procedure times and provide an optimized workflow for fast MR-guided 
prostate biopsy in the clinic.
 Finally, an emerging alternative to in-bore MR-guided prostate biopsy is MRI-TRUS fusion 
biopsy. In this biopsy technique, the strength of diagnostic MRI, i.e. lesion localization and 
visualization, is transferred to the workflow of standard TRUS-guided biopsy by fusing the 
diagnostic MR images with the live ultrasound feed. In this way, TRUS biopsies can be directed 
towards suspicious areas identified on the preceding diagnostic MRI examination. One 
potential advantage is that biopsy can be performed outside of the MR-bore, which could 
make the technique more widely available and extend the utilization of targeted biopsy to 
more centers. Also, procedure times are expected to be shorter than with the in-bore method, 
reducing patient discomfort during the biopsy procedure. Some initial studies have shown 
promising results using this biopsy technique14–16, but validation in larger cohorts is required 
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to determine the clinical accuracy of this biopsy method in comparison with in-bore biopsy17. 
Most likely, a subset of lesions, i.e. larger and/or lesions located in areas that can be easily 
reached using TRUS-guidance, can be identified that are amenable to sampling using MRI-
TRUS fusion biopsy and the appropriate indications for this biopsy technique need to be 
established in the coming years.
MR IMAGING OF CRYOABLATION
The ability of MRI to localize prostate cancer can be combined with its capability to visualize 
ablative therapies to develop minimally invasive prostate cancer treatments under MR-
guidance. One example of such application is MR-guided prostate cryoablation. MRI is 
particularly suitable as a guidance modality for prostate cryoablation due to its superb 
soft tissue contrast capability and near real-time monitoring of the freezing zone in three 
dimensions18,19. MRI allows an excellent depiction of the ice-tissue boundary, with the ice 
ball presenting as a sharply delineated signal void on all conventional pulse sequences20. 
The distinct signal loss of ice is due to an extreme decrease of the T2 relaxation time during 
the transition from liquid into solid state: the mobility of water molecules becomes severely 
restricted, and the relative position of molecules gets arranged in a crystal, allowing fast 
spin-spin relaxation21,22.
 Matsumoto et al. were one of the first to image cryoablation with MRI in the ex-vivo 
and in-vivo liver using a T1-weighted rapid acquisition with relaxation enhancement (RARE) 
sequence23. Since then, several other studies have demonstrated the visibility of the ice-ball 
in different MRI sequences, confirming the ability of MRI to accurately guide cryoablation 
procedures24–27. Tacke et al. performed an in vitro study comparing the appearance of ice 
formation between T1 and T2-weighted spin echo and gradient echo sequences and reported 
T1-weighted imaging to provide higher ice-tissue contrast as compared to T2-weighted 
sequences25. Nevertheless, both sequence types may be very well suitable for monitoring 
of cryoablation and preference for either of the two techniques may vary per application 
depending on the desired soft tissue contrast and spatial or temporal resolution. As the 
cryoablation ice-ball grows relatively slowly, an acquisition time of two to three minutes 
between scans would typically be regarded sufficient19. However, in situations where ablation 
is performed close to critical structures, faster imaging may be required to avoid unwanted 
tissue damage.
 One limitation of MR monitoring of cryoablation is the inability to visualize the thermal 
variations across the tissue. Proximal to the cryoablation zone, a study by Rothgang et al. 
investigated the use of proton resonance frequency shift (PRFS) MR thermometry, however, 
high sensitivity of this technique to ice-ball induced susceptibility artifacts was found to 
considerably influence accuracy of the temperature maps28. In chapter 4, we investigated the 
temperature dependency of T1-weighted MR image contrast around the ice ball as a potential 
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tool to monitor thermal variations directly adjacent to the frozen zone. The hyperintense rim 
observed surrounding the ice in fast T1w imaging visualized the extent of cooled but non-
frozen tissue proximal to the frozen zone.
 Feedback on temperatures achieved within the ice-ball would also be desirable in order 
to assess whether a sufficiently cold end temperature is achieved throughout the entire 
target lesion. However, an effective non-invasive approach for this is still needed. When tissue 
freezes, free water transitions into ice crystals and no MR signal can be detected from these 
water molecules with conventional imaging sequences. Nevertheless, measurable MR signal 
has recently been demonstrated from within frozen tissue using ultrashort echo time (UTE) 
imaging29,30. In nuclear magnetic resonance (NMR) experiments it has been shown that a 
fraction of approximately 10-20% of tissue water remains mobile at freezing temperatures31,32. 
This ‘non-freezable’ water is bound to the hydration layer of macromolecules and is believed 
to be the source of the MR signal observed from frozen tissue in UTE imaging. The ability 
to obtain MR signal from frozen tissue may hold potential for MR thermometry inside the 
ice-ball. Wansapura et al. investigated MR thermometry of frozen tissue based on UTE signal 
intensity and R2* and demonstrated the feasibility of in vivo MR temperature maps during 
cryoablation in a canine experiment30. In another study by Kaye et al, it was determined that 
within the cryogenic temperature range, the relation with temperature of both these MR 
parameters appeared consistent between different tissue types33. In chapter 5, we investigated 
the potential of UTE imaging for 3D MR thermometry of frozen tissue and demonstrated its 
feasibility in an ex vivo setting.
 Nevertheless, further work determining the accuracy and consistency of this approach 
is still required before its use in clinical applications. Also, a robust calibration method is 
needed to translate ex vivo findings to the clinical setting. Finally, when applied in vivo the 
3D UTE sequence presented issues related to out-of-volume magnetization due to non-
selective excitation as well as undersampling to avoid unacceptably long measurement times. 
Therefore, a slice-selective 2D UTE approach may be more promising for MR thermometry of 
frozen tissue in the clinical setting and initial measurements using this technique have recently 
been performed during in-vivo MR-guided renal cryoablation34.
MR-GUIDED PROSTATE CRYOABLATION
In chapter 6, the clinical application of MR-guided focal cryoablation was shown to be feasible 
and safe in patients with locally recurrent PCa after primary radiotherapy, with promising 
functional outcomes and acceptable local control. These results are encouraging, particularly 
considering that curative treatment options in this patient group are limited and most patients 
receive palliative treatment with androgen-deprivation therapy. Nevertheless, a substantial 
proportion of patients showed systemic disease progression within the first year after focal 
salvage cryoablation. Although patients received a pelvic staging MRI examination to exclude 
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lymph node or bone marrow metastases prior to salvage cryoablation, current imaging 
techniques are limited in sensitivity and metastatic screening may have been false-negative 
in these cases. Therefore, improved imaging tools to specifically evaluate lymph node status, 
such as nanoparticle enhanced MR lymfography35,36 or Ga-68 PSMA PET/CT37, are required to 
better select those patients that benefit from local treatment and increase the success rate 
of focal salvage treatment.
 Furthermore, it was shown in chapter 7 that the ice-ball margin correlated with local control 
after MR-guided focal salvage cryoablation. In larger recurrences or lesions located in the 
posterior prostate, it may be more difficult to achieve a sufficient ablation margin and not all 
recurrent prostate lesions may be effectively treated using focal salvage cryoablation. These 
may be important factors to consider when selecting candidates for local salvage treatment.
 Another area of optimization may lie in the computerized planning of procedures. To date, 
treatment planning is performed by measuring the volume of the target tumor and planning a 
transperineal needle path towards it in a medical image viewer. Based on the tumor volume, 
an estimation of the number of cryoneedles needed to fully treat the tumor is made. In this 
process, the addition of a computer model that can simulate the placement of different 
numbers and types of cryoneedles in different configurations and predict the resulting 
ice-ball and 3D temperature isotherms could be of particular value. Ideally, this software 
could also be used intraprocedurally to assess whether the current needle configuration 
will result in sufficiently low end temperatures and an acceptable tumor coverage. In this 
way, interventionalists can make a more profound decision on whether or not to adjust the 
position of needles that are already placed or the need for placing additional cryoneedles on 
an individual patient basis.
 Further improvements may also be made to the process of cryoneedle placement under 
MR-guidance. Although MR fluoroscopy using real-time imaging sequences has recently 
become available, a low spatial resolution and the restricted patient access often limit its 
effective use. Advancements in MR acquisition techniques, developments in short bore wide 
diameter MRI systems and the integration of real-time imaging with needle path planning 
and guidance applications can play an important role in optimizing treatment efficacy and 
further reducing procedure times.
 Finally, MR-guided cryoablation may also prove useful as a minimally invasive treatment for 
renal or lung tumors, painful bone metastases or vascular malformations. Therefore, further 
research may also focus on extending the applications of MR-guided cryoablation to other 
body regions and pathology.
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GENERAL CONCLUSIONS
In conclusion, the results of this thesis have shown that MR-guided biopsy is currently the most 
accurate targeted prostate biopsy technique, however general availability is still restricted. The 
long procedure times of this biopsy method can be overcome with faster targeting techniques, 
which could broaden its use. Furthermore, it was shown that (UTE) MRI holds potential 
for temperature feedback during MR-guided cryoablation procedures. Finally, MR-guided 
focal cryoablation presents a feasible and safe treatment option for localized prostate cancer 
recurrence after previous radiotherapy in carefully selected patients. The ability to achieve 
a sufficiently large ablation margin is important to consider when selecting patients for this 
treatment.
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FUTURE PERSPECTIVES
The advent of prostate MRI has induced a change in the concept of prostate cancer diagnosis. 
It is anticipated that in the coming years targeted biopsy of MRI suspicious lesions will become 
the standard for prostate biopsy, due to its high diagnostic yield of clinically significant prostate 
cancers and reduced detection of low aggressive, indolent prostate cancer38,39. Furthermore, 
the implementation of prostate MRI as a diagnostic test prior to biopsy may lead to a 
substantial proportion (27-51%38,39) of patients that could avoid biopsy at all. This decrease 
in the overall number of prostate biopsies may also be important in terms of reducing biopsy-
related complications and prevention of antibiotic resistance.
 With regard to different targeted biopsy strategies, in-bore MR-guided prostate biopsy 
currently remains the most accurate technique to detect prostate cancer. However, due to 
limitations in general availability and costs, its clinical applicability is restricted. With the 
advent of MRI-TRUS fusion biopsy as an alternative targeted biopsy method, it is essential 
to determine the appropriate indications for each biopsy technique. Hereto, the diagnostic 
accuracy of both techniques should be critically appraised in a multi-center randomized study 
and evaluated with regard to lesion location and size as well as clinical features. Also, cases 
suspicious of recurrence after previous treatment may be more difficult to sample without 
direct MR-guidance and could be an indication to perform in-bore biopsy. Ultimately, a close 
collaboration is needed between urologists, radiologists and pathologists committed to 
integrating these new techniques into the clinic in order to come to an optimized diagnostic 
pathway and provide best quality care to patients confronted with the uncertainty of having 
prostate cancer.
 Similar to the trend in prostate biopsy, a shift is currently evolving in prostate cancer 
treatment. Besides cryoablation, several minimally invasive alternatives to radical whole-
gland treatment, such as focused ultrasound and laser interstitial thermal therapy, have been 
developed over the last few years, which have shown encouraging results in initial patient 
trials40–42. However, each of these therapies has its own unique characteristics and a consensus 
on which focal therapy is best suited to treat localized primary or recurrent prostate cancer has 
not been established. It is imperative to develop standardized inclusion criteria and outcome 
parameters to allow the comparison of studies evaluating MR-guided focal therapies for 
localized prostate cancer. Promising focal therapies should also be compared to standard-
of-care in a randomized controlled trial to demonstrate the long-term outcome in terms of 
efficacy and survival benefit. However, the duration of such studies may prove a limitation 
with respect to the rapid rate of developments in the field and the slowly progressive nature 
of low-aggressive prostate cancer.
 The combination of focal ablative therapies with other forms of (neo)adjuvant treatment 
may be explored as a new option to increase the therapeutic efficacy43. Several investigators 
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have studied the synergy of cryoablation with immune adjuvants to stimulate an anti-tumor 
reaction44,45. Likewise, the combination of ablative therapy with conventional treatments such 
as chemotherapy or radiotherapy has been investigated with the goal of enhancing tumor cell 
death in areas recovering from reversible thermal injury. Experimental animal studies have 
compared radiofrequency ablation followed by either radiotherapy or chemotherapy with 
radiotherapy or chemotherapy alone and showed increased tumor necrosis, reduced tumor 
growth and overall improved survival when treatments were combined46,47. Although these 
investigations are still in the preclinical stage, first results have been promising and applications 
of combination therapies may become clinically available in the future.
 Ultimately, the concept of MR-guided focal therapy holds potential to move from generalized 
whole-gland treatment associated with substantial patient burden to individualized prostate 
cancer treatments with preservation of quality-of-life. The techniques to accomplish this are 
ready and will likely change the landscape of prostate cancer treatments in the decade to 
come.
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In dit proefschrift werden recente ontwikkelingen op het gebied van MRI-geleide prostaat 
interventies gepresenteerd en hun klinische toepassingen geëvalueerd.
 In hoofdstuk 2 werd aangetoond dat op basis van de huidige literatuur in-bore MR-
geleide prostaat biopsie kan worden gezien als een veilige en precieze methode om klinisch 
significante prostaatkanker te detecteren, welke een hoge diagnostische nauwkeurigheid 
bereikt met afname van minder biopten dan gebruikelijk bij TRUS-geleide biopsie. Huidige 
limitaties van in-bore biopsie zijn gelegen in de lange proceduretijden, beperkte algemene 
beschikbaarheid en kosten, welke klinische toepassing van de methode zal beperken tot 
geselecteerde patiënten.
 Hoofdstuk 3 introduceerde een nieuwe targeting methode om in-bore prostaat biopsie 
procedures te versnellen en evalueerde de haalbaarheid van deze techniek tijdens transrectale 
3-T in-bore MR-geleide prostaat biopsie. Twintig patiënten met één suspecte afwijking (CSR) 
met een PI-RADS score ≥4 op diagnostische multiparametrische MRI werden prospectief 
geïncludeerd. Targeting van de CSR werd uitgevoerd onder real-time MRI beeldvorming welke 
werd weergegeven op een tablet computer binnenin de scanner-ruimte. Haalbaarheid en 
technisch succes van de targeting methode werden onderzocht. Tevens werden biopsie- 
en proceduretijden bijgehouden en vergeleken met een gematched referentie cohort 
dat de huidige standaard biopsie procedure had ondergaan. Real-time targeting bleek 
technisch succesvol in alle patiënten en stond biopsie van iedere CSR toe zonder additionele 
herpositionering van de naaldgeleider in 19/20 (95%) van laesies. Tevens toonde onze initiale 
klinische ervaring een substantiële reductie aan in gemiddelde proceduretijd (30%) vergeleken 
met de huidige biopsie procedure.
 In hoofdstuk 4 werd de temperatuur afhankelijkheid van T1-gewogen MRI beeld contrast 
rond een cryoablatie ijsbal onderzocht als een potentiële tool om thermische variaties in 
weefsel direct aangrenzend aan het bevroren gebied te monitoren. Cryoablatie experimenten 
warden uitgevoerd in fantomen (n=3) onder continue MRI beeldvorming met een T1-
gewogen gradient echo sequentie. Genormaliseerde signaal intensiteit werd gerelateerd aan 
temperaturen gemeten met fiberoptische sensoren. Dezelfde sequentie werd gebruikt tijdens 
MR-geleide prostaat cryoablatie in 10 opeenvolgende patiënten en in vivo signaal verschillen 
werden kwantitatief vergeleken met de fantoom data. De cryoablatie ijsbal presenteerde 
zich in de T1-gewogen beelden als een signaalarm gebied omringd door een hyperintense 
rand. Deze hyperintense rand bleek te corresponderen met koude maar nog geen onder nul 
temperaturen (<20°C) in weefsel direct naast de bevroren zone. Eenzelfde beeld contrast 
werd waargenomen zowel in de fantoom studie als in vivo in de menselijke prostaat (root 
mean square verschil tussen de genormaliseerde signaal curves 0.06). Het monitoren van 
deze rand kan mogelijk nuttig zijn in het bewaken van een veilige marge tot vitale structuren 
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tijdens MR-geleide prostaat cryoablatie procedures.
 In hoofdstuk 5 werd het potentieel van 3D UTE beeldvorming onderzocht voor het 
verkrijgen van MRI signaal uit bevroren weefsel en het meten van de temperatuur distributie 
binnen de cryoablatie ijsbal. Cryoablatie experimenten (n=4) werden uitgevoerd in specimens 
van ex-vivo porcine spierweefsel. De eerste drie experimenten dienden als een referentie set. 
UTE MR signaal intensiteit werd gerelateerd aan temperaturen gemeten door fiberoptische 
sensoren en gefit met een mono-exponentiële verval curve om een kalibratie curve te 
verkrijgen. De kalibratie curve werd gebruikt om 3D MR temperatuursbeelden te genereren in 
het vierde experiment, dat diende als validatie set. Statistische analyse werd uitgevoerd om de 
nauwkeurigheid van de voorspelde MR temperatuursbeelden te bepalen. Er werd gevonden 
dat 3D UTE beeldvorming meetbaar MRI signaal kan verkrijgen uit bevroren weefsel tot aan 
temperaturen van -40°C. Voorspelde temperaturen op basis van de MR temperatuurbeelden 
waren sterk gecorreleerd met waarden gemeten met de temperatuursensoren, met een 
gemiddeld verschil van -1.2°C (+4.1 to –6.5). Hiermee heeft dit werk de haalbaarheid 
aangetoond van 3D UTE MR thermometrie van bevroren weefsel tijdens cryoablatie op een 
klinisch 3-T MRI system. Tot aan -40°C was de nauwkeurigheid van de MRI temperatuurbeelden 
binnen klinisch acceptabele grenzen.
 De initiële klinische resultaten van toepassing van focale MR-geleide cryoablatie in 
patiënten met lokaal recidief prostaatkanker na primaire radiotherapie werden gepresenteerd 
in hoofdstuk 6. Een retrospectieve single-center studie werd uitgevoerd in 41 patiënten met 
recidief prostaatkanker na radiotherapie welke MR-geleide cryoablatie ondergingen sinds 
mei 2011 en een follow-up hadden van ≥12 maanden. Haalbaarheid en bijwerkingen werden 
gerapporteerd. Gevalideerde vragenlijsten werden gebruikt om functionele uitkomsten en 
kwaliteit van leven voor en na behandeling te documenteren. Tumor controle werd tevens 
geëvalueerd en was gedefinieerd als afwezigheid van biochemisch recidief volgens de 
Phoenix-criteria alsmede geen ander klinisch, radiologisch of histologisch bewijs voor lokale 
of gemetastaseerde ziekte. Alle procedures bleken technisch haalbaar. Er werd één Clavien-
graad 4 en één Clavien-graad 3b complicatie gezien. Op 12 maanden na behandeling waren 
symptomen van incontinentie en erectiele dysfunctie significant verslechterd ten opzichte van 
scores voor behandeling, maar kwaliteit van leven was niet significant gecompromitteerd. Na 
12 maanden waren 23 patiënten (59%) ziektevrij. Al met al is aangetoond dat focale salvage 
MR-geleide cryoablatie haalbaar is en een acceptabele balans biedt tussen bijwerkingen, 
functionele uitkomst, kwaliteit van leven en lokale tumor controle in de bestudeerde 
patiëntpopulatie. Deze behandeling zou een redelijk alternatief kunnen bieden ten opzichte 
van salvage radicale prostatectomie in geselecteerde patiënten, maar meer gegevens zijn 
nodig voor een definitieve conclusie.
 Hoofdstuk 7  evalueerde ijsbal marges na MR-geleide focale salvage prostaat cryoablatie 
en bestudeerde de correlatie met lokale uitkomst. Een retrospectieve studie is uitgevoerd 
voor 47 patiënten die percutane MR-geleide focale cryoablatie ondergingen voor histologisch 
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bewezen lokaal recidief prostaatkanker na eerdere primaire radiotherapie. Preprocedurele 
diagnostische en intraprocedurele MRI beelden warden geanalyseerd om ijsbal marges in 
drie richtingen af te leiden. Lokale tumor progressie na cryoablatie was gedefinieerd als 
lokaal recidief op follow-up MRI, een positief MR-geleid biopt of biochemisch recidief zonder 
radiologisch bewijs voor gemetastaseerde ziekte. Behaalde ijsbal marges bleken significant 
kleiner voor grotere tumoren of voor posterior gelokaliseerde tumoren. De lokale uitkomst 
op één jaar na focale cryoablatie bleek significant beter te zijn tussen patiënten met een ijsbal 
marge >10 mm (100%), 5-10 mm (84%) en <5 mm (15%). Deze initiële data suggereert dat 
bevriezing minimaal 5 mm voorbij de rand van een op MRI zichtbare recidief prostaat tumor 
moet worden toegepast voor succesvolle cryoablatie, waarbij een ruimere marge wenselijk 
lijkt.
 Afsluitend wordt in hoofdstuk 8 geconcludeerd dat MR-geleide biopsie momenteel de 
meest nauwkeurige gerichte prostaat biopsie methode is, echter de klinische toepasbaarheid 
beperkt zich tot geselecteerde patiënten. Nieuwe, en snellere targeting technieken zouden 
het gebruik van deze biopsie methode kunnen vergroten. Daarnaast lijkt MR-geleide focale 
cryoablatie een acceptabele behandeloptie voor gelokaliseerd recidief prostaatkanker na 
eerdere radiotherapie, maar zorgvuldige patiëntselectie is hierbij essentieel.
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van Rijn met jou liepen regelmatig uit de hand. Een half jaar geleden mocht ik jouw paranimf 
zijn, ik vind het super dat je  vandaag aan mijn zijde wil staan.
Daan, vroeger maakten we samen huiswerk, tenminste zo noemden we die-hard Mario Karten 
toen. Dat er toch nog hoge punten werden gehaald mocht een wonder heten, en ik vind het 
erg bijzonder dat we het beiden tot een proefschrift hebben geschopt. Ik ben vereerd dat je 
vandaag mijn paranimf bent.
Het prostaat-MRI-team, naast Jelle en Jurgen, Marloes, Roel, Patrik en Sjoerd, bedankt dat ik 
zo prettig met jullie heb mogen samenwerken. Ik heb veel van jullie geleerd. Sjoerd, bedankt 
voor je ondersteuning bij alle interventies, je kon jou altijd bellen.
Alle MRI- en angio-laboranten met wie ik over de jaren hebben mogen samenwerken: Richard, 
Miranda F., Miranda W., Angelique, Susan, Gretha, Ivonne, Auke, Pim en Olfat, bedankt voor 
de gezellige dinsdagmiddagen en leerzame MRI ins-en-outs.
Solange, Leonie, Charlotte, Marjolein, Sonja en Germien, jullie stonden altijd klaar om dingen 
te regelen. Of het nou het plannen van afspraken in drukke agenda’s, aanvragen van pasjes 
voor stagiaires of ontvangen van bezoek was, jullie deur stond altijd open. Bedankt! 
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De interventiegroep en klinische onderzoekers, Big-J, Tippie, Wullie, Tim, Joyce, Martijn H., 
Martijn S., Thomas, Mirre, Geke, Annemarijke, Leon, Harm, Annemiek, Marcel, Maarten de R, 
Esther, Eline, Caroline en Derya. Bedankt voor alle inhoudelijke discussies, minder inhoudelijk 
gemijmer en alle onzinpraat maar vooral alle sketches bij de koffieautomaat, gezellige lunches, 
mooie congressen en actieve squashavondjes. Ik vond en vind het leuk dat ik met jullie mag 
samenwerken! 
De BioMR-groep, Andor, Mark, Marnix, Linda, Thiele, Tom P., Fritsel, Bart B., Rutger, Vincent, 
Anne, Isabel, Barbara, Nassim, Franciska en Mike. Bedankt dat ik, als buitenlid, mocht 
deelnemen aan jullie sociale groepsactiviteiten. Ik had alle gezellige biertjes in de Aesculaaf, 
paardenplaatjes downloaden met Frits en de vele taartmomenten in de GLC niet willen 
missen!
En uiteraard mijn kamergenoten, van Asten (lul), Maarten, Bart, Evita en Weiqiang. Tsja, 
wat moet ik hier zeggen. Man, man, man, man. Ik kon me geen beter kantoor wensen, vijf 
jaar middenin live opnames van Debiteuren Crediteuren, gemixt met Dumpert, dagelijkse 
sneeuwhoogte updates en Hoch die Hände. Ik denk dat we iedere dag lol hebben gehad. 
Bedankt voor alle gezelligheid! P.S: Bart, de snoeppot is (nog steeds) leeg.
Ook mijn familie, studievrienden, vrienden uit Elst en Nijmegen en (oud-)huisgenoten, bij 
jullie kon ik altijd terecht voor een goed gesprek of een gezellig biertje. Bedankt voor alle 
belangstelling over de afgelopen jaren. Of het nou ging over mijn promotie, werk of juist 
ook alles daarbuiten, jullie hadden altijd een luisterend oor. In het bijzonder de Lamies: Joël, 
Michiel, Joep, Jimmy, Daan en Juul. Altijd als we elkaar weer zien is het meteen gezellig. 
Bedankt voor al het lachen, ik vind het erg bijzonder dat we elkaar na al die jaren nog steeds 
regelmatig zien.
Mark en Ruben, broers, bedankt voor alle gezelligheid, vroeger thuis en nu als we weer eens 
in Elst op bezoek zijn. Ik zie ernaar uit nog vaak samen te lachen, potjes Risk te spelen of een 
berg op te fietsen met Clerc. Bedankt dat jullie er voor me zijn. Ik ben trots jullie als mijn 
broers te hebben.
DANKWOORD
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Lieve papa en mama, jullie staan altijd onvoorwaardelijk voor ons klaar. Van jullie mocht ik 
mijn hart volgen. Daardoor ben ik waar en wie ik nu ben. Jullie hebben mij altijd gesteund. 
Dat gevoel is nergens mee te vergelijken. Ik ben jullie dankbaar en bewonder jullie om wie 
jullie zijn. Ik hou van jullie.
Lieve Lieke, we kennen elkaar nog maar ‘even’.
Toch voelt dat niet zo. Ik vind je mooi. En ik voel me thuis bij jou.
Ik kijk ernaar uit samen nog vele avonturen te beleven.
You won’t find faith or hope down a telescope,
You won’t find heart and soul in the stars,
You can break everything down to chemicals,
But you can’t explain a love like ours.
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